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The gastrointestinal (GI) tract is colonized with complex microbial communities, known 
as the microbiota, that contribute to the health of the host. The intestinal microbiota plays 
an important role in determining susceptibility to enteric infection and therapeutic 
response to cancer treatment. The composition of the microbiota is known to influence 
the efficacy of a range of cancer therapies. We found that differences in the microbiota’s 
composition affects patients’ risk of developing inflammatory complications of 
immunotherapy. Increased representation of the Bacteroidetes phylum as well as B 
vitamin biosynthesis pathways are correlated with resistance to checkpoint-blockade-
induced colitis. The microbiota’s composition is also known to impact the colonization 
density of antibiotic-resistant pathogens, an important cause of bacteremia in cancer 
patients receiving allogeneic hematopoietic stem cell transplants. We found that obligate 
anaerobes provide colonization resistance to Klebsiella pneumoniae, which is inhibited 
by short-chain fatty acids. Once colonized, enteric pathogens can evolve in the GI tract. 
This evolution can be tracked by the accumulation of single nucleotide polymorphisms 
(SNP) over time. In a mouse model of Enterococcus faecium colonization, SNPs were 
acquired at a rapid and regular rate, enabling us to study its diversification in real-time. 
Our work indicates that E. faecium can rapidly adapt in the gut by acquiring mutations in 
the pencillin-binding protein 5 while exposed to long-term ampicillin treatment.  
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1.1 OVERVIEW   
The GI tract harbors a rich community of bacteria, reaching densities as high as 1011-1012 
CFU/g (1). Intestinal microbes have coevolved with their hosts over millennia and aid in 
numerous functions from energy harvesting to immune system development (2). The 
intestinal microbiota of healthy individuals is composed of a diverse consortium of 
bacteria (3-5). Individuals harbor a range of bacterial compositions, consisting of 
hundreds of microbial strains in the colon that mainly fall into two major phyla: gram-
negative Bacteroidetes and gram-positive Firmicutes (3,6,7). In addition to variations 
among individuals, differences in community structure are also found across body sites 
that exhibit different levels of stability over time, such as between the stable lower (fecal) 
and variable upper (oral) regions of the alimentary canal (8). The composition of the 
intestinal microbiota impacts the health of the host broadly as it has been associated with 
the development of diseases ranging from obesity, arthritis, Parkinson’s, depression, to 
cancer (9-13). 
Following antibiotic-induced perturbations of the microbiota’s composition, colonization 
resistance is impaired, which allows pathogens such as Enterococcus faecium and 
Klebsiella pneumoniae to colonize the GI tract and rapidly reach high densities. In this 
introduction, we discuss how pathogens expand and evolve within hosts during infections 
(section 1.2). We then discuss mechanisms that commensal microbes utilize to prevent 
enteric infection with a particular focus on these two pathogens (section 1.3) and how 
rationally designed bacteriotherapy may rescue resistance in colonized patients (section 
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1.4). We conclude with a discussion of the role that the composition of the microbiota 
plays in maintaining mucosal homeostasis and modulating the effect of drug therapy 
(section 1.5).  
1.2. EXPANSION AND DIVERSIFICATION OF COLONIZING PATHOGENS 
WITHIN PATIENTS 
Administration of broad-spectrum antibiotics allows bacterial pathogens to expand 
dramatically in the gut by perturbing this sensitive microbial ecosystem (14-17). The 
clinical consequences of vancomycin-resistance Enterococci (VRE) serves as an 
excellent case study. VRE can expand to 99% of the intestinal lumen’s microbiota in both 
antibiotic-treated mice and hospitalized patients (15). Dense colonization is associated 
with translocation into the bloodstream and subsequent bacteremia (15,16). In patients 
undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), VRE 
colonization was found in over one-third of recipients and these dominated patients had a 
9-fold greater risk for VRE bacteremia (16). This risk persists over time; ampicillin 
administration leaves mice susceptible to VRE colonization for up to 4 weeks post-
treatment, and VRE stably persists in the cecum for at least 60 days (15). Bacterial 
pathogens and commensals can accumulate mutations as they adapt to the host 
environment during acute infection and chronic colonization. How microbes evolve 
within patients is of clinical importance. Colonizing pathogens improve their fitness 
within a host by increasing virulence, drug resistance and immune evasion (18). The 
genetic changes acquired within patients can also be used to track infections, providing 
higher-resolution insight into the dynamics of patient-to-patient spread than traditional 
typing methods (19-22).  
SNP-based genomic comparisons have been employed to carefully characterize bacterial 
evolution. During chronic colonization in patients, bacteria acquire genetic changes 
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within months and develop coexisting, diverging communities (18, 23). Genes that are 
downstream targets of antibiotics have been mutated across different patients harboring 
the same pathogen, demonstrating the development of antibiotic resistance in realtime 
(18,24,25). With shotgun metagenomic sequencing, the relative abundances of different 
bacterial sublineages harbored in a single patient can be measured by determining the 
relative SNP frequencies in the total population. In patients intestinally colonized with 
Bacteroides fragilis, two evolutionary patterns emerged from the inferred population 
dynamics – one of clonal interference between two subclades, and a “sweep” in which a 
nonsynonymous mutation in a polysaccharide importer that became fixed in one of the 
lineages (26). Such dynamic events in vivo suggest that within-host genetic changes drive 
adaptation to the host within relatively short time scales. However, the within-patient 
evolution of VRE, a prevalent hospital-associated pathogen that can intestinally colonize 
patients for months, has not been well characterized. Understanding within-host VRE 
diversification can help inform how drug resistance develops, how and when patients 
acquire VRE in the GI tract, and provide potential treatment targets of genes important 
for long-term persistence.  
1.3. THE BACTERIAL INTERACTIONS THAT UNDERPIN COLONIZATION 
RESISTANCE  
1.3.1. Colonization resistance is mediated by the intestinal microbiota.  
The intestinal microbiota prevents enteric pathogens such as Clostridium difficile and 
VRE from colonizing the gut through a process known as colonization resistance 
(15,27-30). Antibiotic treatment abrogates colonization resistance by depleting large 
communities of intestinal commensal microorganisms, particularly anaerobic bacteria, 
that mediate this defense (27,31-33). Repopulating the GI tract with a defined community 
of commensal microbes can effectively eliminate pathogens from the GI tract (34,35). 
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Commensal microbes facilitate clearance of enteric pathogens by various means (36-38). 
Broadly, commensals employ a variety of mechanisms to prevent infection: (i) indirect 
elimination that relies on activating the innate mucosal immunity or continual 
maintenance of mucosal barrier integrity, and (ii) direct antagonism through competition 
for nutrients or the production of inhibitory molecules.  
1.3.2. Indirect inhibition involves activation of innate host immune defenses and 
maintenance of the mucosal barrier.   
Intestinal microbes can stimulate innate receptors on immune cells and induce the 
production of antimicrobial peptides in other intestinal cell types. Paneth cells and 
intestinal epithelial cells produce RegIIIγ, a C-type lectin driven by Toll-like receptor 
(TLR) signaling with bactericidal activity against gram-positive bacteria (39-41). 
Secreted RegIIIγ kills bacteria by binding to peptidoglycans of the bacterial cell wall and 
forming pores (42). Antibiotic treatment reduces expression of RegIIIγ and, in mice, 
increases susceptibility to VRE colonization and bacteremia (43). Oral administration of 
lipopolysaccharide mimics commensal microbial signals and restores RegIIIγ production, 
thereby increasing resistance to VRE (43). A signaling pathway driving RegIIIγ 
expression was delineated by administration of the bacterial TLR5 ligand, flagellin. 
Flagellin administered intravenously stimulates the CD103+ CD11b+ subset of dendritic 
cells to produce interleukin-23, which drives the interleukin-22-mediated production of 
RegIIIγ by intestinal epithelial cells (44,45).  
Intestinal microbes are separated from the mucosal epithelium and its distal lamina 
propria by mucus that coats the epithelial surface. The colonic epithelium is covered by a 
dense 50-µm-thick inner mucin layer composed primarily of Muc2 and a less dense outer 
stratum (46). Maintenance of a healthy epithelial barrier and intact gut physiology, such 
as gastric acid production, inhibits bacterial colonization of the GI tract (47). Goblet cells 
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produce mucin, and secretion is stimulated by commensal bacteria in a MyD88-
dependent manner (48-50). Following antibiotic treatment, the mucin layer thins; without 
a robust physical barrier, intestinal microbes can directly access and potentially breach 
the epithelium (51). Both the density and composition of the mucus layers limit bacterial 
invasion. RegIIIγ is associated with mucin and reduces the density of intestinal bacteria 
near epithelial cells (52-54). Intact mucin production limits the invasive potential of 
intestinal enterococci (55). VRE is spatially segregated from the intestinal mucus layer 
and adjacent epithelium even after antibiotic treatment with its notable mucin reduction 
(55). Conversely, K. pneumonaie can reside in the inner mucus layer and translocate into 
the mesenteric lymph nodes following intestinal colonization. Co-colonization of mice 
with VRE and K. pneumoniae, which can more deeply penetrate the mucus coating, 
enables VRE to gain access to the mesenteric lymph nodes, possibly by K. pneumoniae-
induced alterations to the mucin composition (55).  
1.3.3. Direct inhibition involves competition for nutrients and the production of 
inhibitory molecules.  
Commensals can outcompete pathogens for essential nutrients. Commensal E. coli clears 
Citrobacter rodentium from the gut by consuming the monosaccharides that both require 
for growth (56). Commensal E. coli can also outcompete a pathogenic E. coli strain 
through nutrient deprivation (57). Commensal microbes can inhibit pathogen colonization 
by producing toxic substances such as bacteriocins, which are small molecules with 
antimicrobial activity. Bacteriocin-coding genes are commonly harbored on plasmids in 
enterococci. Commensal E. faecalis strains that express a pheromone-responsive 
conjugative plasmid encoding bacteriocin bac-21 outcompeted VRE lacking it (58). 
Lactococcus lactis strains engineered to express bacteriocins significantly inhibited VRE 
growth in vitro (59). Oral administration of bacteriocin-producing L. lactis MM19 
eliminated VRE at a faster rate from the gut of mice than mock treatment (60).  
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Intestinal commensals metabolize complex carbohydrates to short-chain fatty acids 
(acetate, propionate, and butyrate), which can have inhibitory effects on gram-negatives. 
Acetate directly inhibits the growth of E. coli in vitro through the accumulation of its 
anions in the cytoplasm which reduces the intracellular pH (pH-i) and thereby increases 
osmotic pressure (61). This effect is buffered by the amount of glutamate in the cell and 
recovery from acetate-induced pH-i is associated with synthesizing more glutamate (61). 
Additionally, the depletion of methionine and glycine contribute to the growth inhibition 
and can be restored with amino acid supplementation (62,63). This effect is due to 
intermediates in the amino acid biosynthetic pathways accumulating (63).  
1.3.4. Evolved mechanisms of commensals to combat pathogens of same species.  
Commensal enterococci have developed sophisticated mechanisms to eliminate 
exogenous enterococcal competitors from the gut. Recent studies have examined the 
colonization dynamics between enterococcal commensals and healthcare-related isolates 
in the GI tract. While resistant isolates outcompete sensitive enterococci in the context of 
antibiotic pressure, intestinal colonization in patients declines following discharge (64). 
In in vivo competition assays that compared the colonization ability of E. faecium strains 
in antibiotic-treated mice, commensal isolates outcompeted hospital-derived strains after 
2 weeks (65).  
As mentioned in the previous section, commensal E. faecalis that express bacteriocin 
bac-21 carried on the plasmid pPD1 that can target VRE, and this plasmid is quickly 
transferred to naive intestinal commensals by conjugation (58). Pheromones are secreted 
short lipoprotein signal peptide fragments that act as chemical messengers between 
bacteria and can mediate cell death. The multidrug-resistant E. faecalis isolate V583 
harbors a plasmid called pTEF2 that renders it susceptible to a killing mechanism 
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induced by commensal-derived pheromone cOB1 (66). Bacteriophages, or phages, are 
viruses that selectively infect and kill microbes. Given their selective killing, phages 
could be used therapeutically as a narrow-spectrum antimicrobial. E. faecalis strains that 
contain the bacteriophage ɸV1/7 in their genetic repertoire possess a growth advantage 
over related bacteria that lack it through phage-mediated lysis of competitors (67). In a 
mouse model of VRE bacteremia, intraperitoneal injection of ENB6 phage protected all 
mice when administered shortly after lethal VRE challenge and half of the mice when 
administered after the mice were moribund (68). 
1.4. THERAPEUTIC POTENTIAL OF MICROBIOTA TRANSPLANTATION 
1.4.1. Current state of fecal microbial transplantation to clear intestinal antibiotic 
resistant E. faecium and K. pneumoniae.  
Given the rise of antibiotic resistance, fecal microbiota transplantation (FMT) is an 
attractive alternative therapy to treat antibiotic-resistant pathogens and is an area of active 
research. FMT is remarkably successful at curing chronic, intractable C. difficile infection 
(69). A secondary analysis of a study involving patients with recurrent C. difficile 
infection showed that a human-derived FMT can reduce VRE colonization (70). 
However, the risk of unwittingly transmitting pathogenic microorganisms through FMTs 
is not insignificant, especially since many constituents of the microbiota have only 
recently been identified, if not characterized. This concern is particularly relevant to 
patients colonized with VRE, who are often immunocompromised. Researchers are 
actively exploring methods to perfect the acquisition of transferred bacteria and define 
critical members of FMTs that target infectious agents (71,72). 
To date, clinical trials studying the impact of fecal bacteriotherapy on intestinal carriage 
of VRE and multi-drug resistant Enterobacteriaceae are limited. An FMT used to treat a 
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patient with recurrent urinary tract infections (UTIs) eliminated intestinal P. aeruginosa 
that was causing the bladder infection but failed to resolve E. coli colonization (73). In a 
trial of 20 immunocompromised patients, antibiotic-resistant K. pneumoniae was 
undetectable in 65% of colonized patients following FMT, with an 89% efficacy in those 
who did not receive concurrent antibiotics (74). A few studies demonstrate the efficacy of 
probiotic bacteriotherapy to clear VRE from the gut. In a randomized study of 21 renal 
patients harboring VRE in their GI tract, ingestion of a yogurt supplemented with 
Lactobacillus rhamnosus GG reduced VRE density to the limit of detection in all patients 
receiving the probiotic (75). VRE burden decreased during a 3-week oral 
supplementation with L. rhamnosus GG in a randomized clinical trial of 61 children (76). 
This effect was not seen with 5-week administration of L. rhamnosus Lcr35 in a 
randomized study of nine patients (77). A 2-week course of L. rhamnosus GG 
administration in 11 patients with comorbidities also did not affect VRE colonization 
(78). Studies of enterococcal probiotics have failed to demonstrate their potential to limit 
drug-resistant enterococci colonization. In a prospective cohort study with over 500 
hospitalized patients, a 10-strain mixture that contained E. faecium and numerous 
Lactobacillus isolates did not prevent ampicillin-resistant E. faecium acquisition (79). 
In the first study of its kind for VRE, a defined consortium of commensals was identified 
as capable of restoring colonization resistance in mice (30). Antibiotic-treated mice were 
orally administered diluted doses of fecal microbiota from a colony of mice that had 
received ampicillin for over 15 years. Bacterial isolates in low-dose fractions that 
conferred resistance to VRE were identified, cultured, and administered in discrete 
combinations to mice maintained on ampicillin. Through a series of leave-one-out 
adoptive transfers, a minimum of four anaerobic isoates were found to successfully 
prevent and clear VRE from the gut: Blautia producta, Clostridium bolteae, Bacteroides 
sartorii, and Parabacteroides distasonis (30). Of the four-commensal mixture, B. 
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producta was shown ex vivo as the member that directly inhibits VRE growth, although 
the exact mechanism remains unknown. An open question in the field is whether a 
precise mixture of commensal isolates can be identified and used to clear K. pneumoniae 
colonization as had been done for C. difficile and VRE.  
1.5.  THE HOST-MICROBE RELATIONSHIP  
1.5.1. The intestinal microbiota promotes homeostasis and mucosal tolerance.   
Microbial species from a variety of genera such as Bacteroides, Clostridium and 
Faecalibacterium can induce the expansion of T-regulatory cells and stimulate the 
production of anti-inflammatory cytokines. A 17-strain collection of Clostridia isolates 
from clusters IV, XIVa and XVIII increased the number of Foxp3+ Treg cells that 
accumulated in the colonic mucosa and improved survival in an OVA-induced intestinal 
allergic murine model (80). Faecalibacterium prausnitzii has been found in lower 
abundance in Crohn’s disease patients, and oral inoculation into mice with acute TNBS-
induced colitis minimized pathology (81). Polysaccharide A produced by Bacteroides 
fragilis stimulates Foxp3+ Treg cell proliferation and IL-10 cytokine production (82). In 
a large screen of mono-colonized gnotobiotic mice, Bacteroides strains were the most 
successful at inducing colonic Foxp3+ Treg accumulation (83). Short chain fatty acids 
(SCFAs), metabolic byproducts produced by commensal microbes such as members of 
17-strain Clostridia consortium, boost the differentiation of peripheral Tregs (84).  
1.5.2. The microbiota mediates the host response to drug treatment.  
The immunomodulatory capacity of the microbiota extends to mediating the efficacy of 
drugs that target immune system, specifically of cancer drugs. In the case of anti-PD-L1 
and anti-CTLA-4 blockade, as well as CpG-oligonucleotide immunotherapy and 
cyclophosphamide, therapeutic response is affected by the intestinal microbiota. 
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Bifidobacterium boosted antitumor immunity by increasing T cell numbers in the 
melanoma tumor microenvironment following PD-L1 checkpoint blockade (85). B. 
fragilis was correlated with reduced melanoma tumor burden following CTLA-4 
checkpoint blockade, and this effect was abrogated by antibiotics (86). Commensal 
intestinal bacteria enhanced TNF and ROS production during CpG-oligonucleotide 
therapy that reduced solid tumor growth (87). Increased intestinal epithelial permeability 
caused by cyclophosphamide led to bacteria translocating to lymph nodes and thereby 
stimulating Th17 cell development that is required for the drug’s antitumor effects (88). 
Three studies were published simultaneously in 2018 detailing the microbiota’s role in 
mediating tumor responses to anti-PD-1 immunotherapy in cancer patients (89-91). An 
open question in the field was whether, like with treatment efficacy, the microbiome 
plays a role in the development of immune-mediated, new-onset colitis in patients and if 
the microbiota’s composition can be used to predict toxicity.  
1.6. SUMMARY AND CHAPTER OUTLINE   
The overall aim of this thesis is to understand the role of the microbiota in modulating 
disease states (such as colitis and infection) and, after expansion following dysbiosis, 
how opportunistic pathogens evolve and adapt within the gut environment. In Chapter 1, 
we identify microbiome biomarkers that predict patient’s risk of developing checkpoint-
blockade-induced colitis. In Chapter 2, we correlate obligate anaerobes with resistance 
to Klebsiellsia pneumoniae colonization. In Chapter 3, we characterize the temporal 
dynamics of within-host VRE evolution.  
* Adapted from: Dubin K, Pamer E. 2017. Microbiol Spec 5(6)  
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CHAPTER TWO 
INTESTINAL MICROBIOME ANALYSES IDENTIFY MELANOMA PATIENTS AT 
RISK FOR CHECKPOINT-BLOCKADE-INDUCED COLITIS * 
2.1. INTRODUCTION  
Healthy individuals harbor distinct microbial populations in their intestinal tract that vary 
markedly in composition. The complexity and plasticity of the intestinal microbiota 
represent a significant challenge to the host’s immune defenses, which must balance 
immune tolerance of beneficial microbes with inflammatory responses against pathogens. 
Certain bacterial species are essential for maintaining a tolerogenic state in the mucosa. 
Identifying the microbial species that promote homeostasis or drive inflammation has 
remained a challenge in the clinical context, in particular with chronic inflammatory 
conditions such as inflammatory bowel disease. Certain bacteria preferentially expand 
following inflammation, which alters the microbiota’s composition (92-94). Thus, as 
most patients seek medical attention after inflammation has developed, it is difficult to 
define the microbiota composition that precedes the development of colitis. Ipilimumab, 
a monoclonal antibody that blocks the co-inhibitory molecule cytotoxic T-lymphocyte-
associated antigen-4 (CTLA-4), is an immunomodulatory therapy that provides effective 
treatment against metastatic melanoma (95). Inhibition of CTLA-4 signaling dampens 
negative regulation of T cells, thereby enhancing anti-tumor responses. Within the first 16 
weeks of treatment, roughly one-third of recipients develop intestinal inflammation as a 
result of mucosal immune dysregulation (96-98). The high incidence of colitis in patients 
receiving ipilimumab provides an opportunity to characterize the colonic microbiota 
* Dubin K, et al. 2016. Nat Commun (7):10391. PMID: 26837003 
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before the development of intestinal inflammation.  
Herein we use next-generation metagenomic sequencing to identify biomarkers that are 
associated with resistance to new-onset, immune-mediated colitis in the context of 
immune checkpoint-blockade therapy. Increased fecal abundance of the Bacteroidetes 
phylum and three of its families (Bacteroidaceae, Rikenellaceae and Barnesiellaceae), as 
well as microbial genetic pathways involved in polyamine transport and B vitamin 
biosynthesis, are correlated with resistance to the development of colitis following 
CTLA-4 blockade. This study provides a novel view of the intestinal microbiota before 
the development of colitis and offers insight into preventive treatments for patients at risk 
of adverse inflammatory events following immunologic checkpoint blockade. 
2.2. RESULTS  
2.2.1. Colitis development in patients following CTLA-4-blockade.  
We analyzed the intestinal microbiota of 34 patients enrolled in a prospective study to 
correlate pre-colitis fecal composition with the subsequent development of checkpoint-
blockade-induced colitis. The patients in this study ranged in age between 28 and 85 and 
were diagnosed with metastatic melanoma. In general, fecal samples were obtained from 
patients prior to the first dose of ipilimumab (30/34), although in 2 patients who 
subsequently developed inflammation and 2 patients who remained inflammation free, 
samples were obtained after initiation of ipilimumab, but before the onset of colitis. Of 
the 34 patients, 10 were diagnosed with gastrointestinal inflammation between 13 and 57 
days after initiation of ipilimumab (Fig. 2.1a). Patients who did not develop 
gastrointestinal inflammation following CTLA-4 blockade are herein referred to as 
Colitis-Free (C-F), and patients who experienced inflammatory complications after 
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CTLA-4 blockade are referred to as having Progressed to Colitis (PtC). Patients were 
assigned a colitis score by retrospective chart review, which ranged from no diarrhea 
(score 0) in C-F patients to severe colitis (score 4) in PtC patients (Table 2.1). There were 
no differences in age or gender between C-F and PtC patients (Table 2.1). Additionally, 
40% of PtC patients and 50% of C-F patients were treated with systemic cancer therapy 
administered either prior to (14/16) or both before and during (2/16; both C-F) 
ipilimumab treatment course (Table 2.1).  
 
Figure 2.1 | Colitis-Free and Progressed to Colitis patients harbor distinct microbial populations. a) 
Fecal sample collection (blue circle) and the onset of colitis (red triangle) are shown at the indicated time-
points during treatment with ipilimumab, a monoclonal antibody that blocks CTLA-4-signaling. Dates are 
relative to first dose of treatment. An average abundance >0.01% was used as the threshold for considering 
an OTU to be present within fecal samples in either patient group (OTUs, n=578); OTUs at an abundance 
of 0.01% were not considered to be present in the patients’ microbiota. Using this definition, we calculated 
b) the number of OTUs present in C-F patients only (purple), PtC patients only (turquoise), or shared 
between the patient groups (blue) in a scaled Venn diagram. c) The mean relative abundance of OTUs, d) 
total abundance of OTUs, e) distribution of OTUs that are present in C-F patients only, PtC patients only or 
shared between the patient. C-F patients, n=24; PtC patients, n=10. OTUs, operational taxonomic units.  
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Table 2.1 | Patient characteristics and sample collection. Colitis score was determined by retrospective 
chart review using CTCAE, with scores ranging from 0 (no diarrhea) to 4 (severe colitis). Patient age was 
defined as of the first dose of ipilimumab and rounded down to the nearest integer. Patients’ history of 
systemic cancer therapy was determined by retrospective chart review. A total of 16 patients received 
systemic cancer treatment, either prior to ipilimumab monotherapy (14/16) or both before and during 
ipilimumab treatment course (2/16). The symbol (+) indicates treatments that are given concurrently, while 
symbol (;) indicates treatments administered at different times. The symbol (*) indicates systemic cancer 
treatment administered both before and during ipilimumab therapy. C-F patients, n=24; PtC patients, n=10. 
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2.2.2. Composition of the intestinal microbiota prior to colitis.  
In order to characterize the intestinal microbial composition prior to immune-mediated 
colitis, fecal samples were submitted for bacterial microbiota profiling using 16S rRNA 
sequencing on the Illumina MiSeq platform. C-F and PtC patients harbored intestinal 
microbiota with similarly complex microbial populations and shared 239 of 578 
operational taxonomic units (OTUs, defined at a 97% sequence similarity) (Fig. 2.1b). 
These 239 shared OTUs represent 79% and 83% of the total OTU abundance in the C-F 
and PtC patient groups, respectively (Fig. 2.1c,d), and many were present in 5 or more 
patients (Fig. 2.1d). In contrast, OTUs that were either associated with only C-F or PtC 
patients were generally detected in fewer than 5 patients (Fig. 1e). The OTUs that are 
shared between the two patient groups are more evenly distributed. Roughly 20% of 
shared OTUs are found in over half of all patients (Fig. 2.1e). These differences in the 
distribution of OTUs among the patient groups did not significantly impact the overall 
biodiversity (Fig. 2.2a,b). Microbial richness, reflecting the number of unique phylotypes 
within a given sample, was found to be similar between patients who developed CTLA-4 
blockade-induced colitis or remained colitis-free (Fig. 2.2c,d). 
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Figure 2.2 | Colitis-Free and Progressed to Colitis patients have similar levels of intestinal microbial 
diversity. Biodiversity is estimated by a) the Inverse Simpson index and b) the Shannon index for each 
patient sample. Richness is measured by c) the Chao estimator and d) rarefaction curves. Mann-Whitney 
tests were used to compare microbial diversity parameters between the patient groups. Height of bar 
represents the mean, error bars represent standard deviation. C-F, Colitis-Free; PtC, Progressed to Colitis. 
C-F patients, n=24; PtC patients, n=10. n.s., not significant. 
To examine the intestinal microbiota structure between patient groups, we plotted the 
relative frequencies of bacterial phylotypes at the taxonomic level of family for each 
patient. Although C-F and PtC patients shared many bacterial taxa that belong to the 
Firmicutes phylum, C-F patients harbor a greater proportion of microbes within the 
Bacteroidaceae family (Fig. 2.3a). Our taxonomic classifications based on 16S 
sequencing data were similar to those found when applying MetaPhlAn to shotgun 
metagenomic sequencing data on a subset of this patient cohort, although the proportions 
of some bacterial phyla vary between the two methods (Fig. 2.4). To illustrate the 
microbiota composition with finer resolution, we plotted the relative abundances of 146 
OTUs at 0.1% or greater mean abundance. While broad swaths of the microbiota are 
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found at similar frequencies between patients, microbes within the Bacteroidetes phylum 
are underrepresented in the patients who developed new-onset, immune-mediated colitis 
(Fig. 2.3b). 
 
Figure 2.3 | Composition of the intestinal microbiota between C-F and PtC patients. a) OTUs with an 
average abundance >0.01% within either patient group were classified at the family taxonomic level. 
Families with an average abundance of 2.5% or maximum abundance of 5% are plotted. Each bar 
represents the fecal microbial composition of one patient. b) The relative abundances of the 146 bacterial 
OTUs in C-F and PtC patients represented in a heat map. OTUs plotted were present at a mean abundance 
of >0.1%. Patients are ordered by CTCAE-based colitis score. C-F patients, n=24; PtC patients, n=10. 
OTUs, operational taxonomic units. Actino, Actinobacteria; Bact, Bacteroidetes; Firm, Firmicutes; Proteo, 
Proteobacteria; Verr, Verrucomicrobia. 
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Figure 2.4 | Accuracy of bacterial taxonomic classification. a) 16s sequencing reads were clustered into 
OTUs by 97% sequencing homology. Relative abundances of OTUs that met our defined threshold (of an 
average abundance >0.01% in either patient group) were plotted by phylum. Bar plots were constructed 
only for those patients whose samples were subjected to shotgun metagenomic sequencing. b) Relative 
abundances of shotgun metagenomic sequencing reads were calculated using MetaPhlAn and plotted by 
phylum. OTUs, operational taxonomic units. C-F patients, n=12; PtC patients, n=10. 
2.2.3. Members of Bacteroidetes phylum are associated with resistance.  
To further explore the relationship between specific bacterial members of the intestinal 
microbiota and development of CTLA-4 blockade-induced colitis, we stratified patients 
by the severity of inflammation and performed a Spearman rank correlation test on the 
relative abundances of bacterial species grouped at different taxonomic levels. This 
analysis revealed that taxa within the Bacteroidetes phylum are more prevalent in C-F 
patient samples (Fig. 2.5a). The relative abundance of OTUs classified as Bacteroidetes, 
as well as the number of OTUs assigned to the phylum, were significantly higher in C-F 
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patients (Mann-Whitney test, p<0.05) (Fig. 2.5b,c). Within the Bacteroidetes phylum, the 
prevalence of Bacteroidaceae, Rikenellaceae, and Barnesiellaceae is significantly more 
abundant in patients resistant to Ipilimumab-induced colitis (Mann-Whitney test, p<0.01, 
p<0.05, p<0.05, respectively) (Fig. 2.5d,e,f). While the composition of the intestinal 
microbiota can vary over the lifetime of an individual, there was no association between 
patients’ age and the abundance of Bacteroidetes (Fig. 2.6). 
 
Figure 2.5 | Increased abundance of the Bacteroidetes phylum and select families correlates with 
protection from colitis. OTUs with an average abundance greater than 0.01% within either patient group 
were binned at different levels of taxonomic classification (phylum, class, order, family, genus). a) 
Correlation of bacterial phylotypes to CTCAE-based colitis score by Spearman analysis. Taxa with p-
values <0.05 are plotted. b) Relative abundance of the phylum Bacteriodetes in PtC and C-F patients. c) 
The number of OTUs assigned to the Bacteroidetes phylum in each patient group. Relative abundances of 
the families d) Bacteroidaceae, e) Rikenellaceae, f) Barnesiellaceae within the Bacteroidetes phylum in PtC 
and C-F patients. P-values were determined by Mann-Whitney test. Height of bar represents the mean, 
error bars represent standard deviation. C-F patients, n=24; PtC patients, n=10. r, Rho coefficient; p, p-
value; OTUs, Operational Taxonomic Units.  
!19
 
Figure 2.6 | Correlation between patient age and relative abundance of Bacteroidetes phylum. Patient 
age was defined as of the first dose of ipilimumab. OTUs with an average abundance >0.01% within either 
patient group were grouped by phylum. Spearman correlation test was performed on age and Bacterodietes 
abundance. r, Rho coefficient; p, p-value; OTUs, operational taxonomic units. C-F patients, n=24; PtC 
patients, n=10. 
2.2.4. Specific microbial modules are associated with protection.  
To evaluate the genetic pathways that may play a role in the development of immune-
mediated colitis, we performed shotgun metagenomic sequencing on the 10 PtC and 12 
C-F patient fecal samples. Sequencing reads were processed using HUMAnN and 
assigned to KEGG (Kyoto Encyclopedia of Genes and Genomes) modules. The microbial 
modules that comprised patients’ intestinal microbiota were broadly similar between C-F 
and PtC patients (Fig. 2.7a). We conducted a univariate test for associations between 
colitis status and the 102 microbial modules using linear discriminant analysis effect size 
(LEfSe). We found that the spermidine/putrescine polyamine transport system and three 
modules involved in the biosynthesis of B vitamins (riboflavin (B2), pantothenate (B5) 
and thiamine (B1)) were more abundant in C-F patients (Fig. 2.7b). After stratifying 
samples by colitis status, Spearman analysis identified the polyamine transport system 
and thiamine (B1) modules as correlated with resistance to the development of colitis 
(Fig. 2.7c). The relative abundances of the aforementioned pathways are significantly 
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enriched in C-F patient samples (Mann-Whitney test, p<0.05 for all modules) (Fig. 2.7d). 
In addition, an additional module involved in the biosynthesis of the biotin (vitamin B7) 
was found in greater abundance in C-F patients (Mann-Whitney test, p<0.05).  
 
Figure 2.7 | Bacterial modules involved in polyamine transport and vitamin B synthesis are 
associated with resistance to colitis. a) Relative abundance of 102 microbial KEGG modules in C-F and 
PtC patients. b) Association of genetic modules with colitis status by linear discriminant analysis effect size 
(LEfSe) analysis. Modules with LDA score >3 are plotted. c) Correlation of genetic modules to colitis score 
by Spearman analysis. Modules with p-values <0.05 are plotted. d) Relative abundances of modules 
associated with C-F patients. P-values were determined by Mann-Whitney test. Height of bar represents 
mean, error bars represent standard deviation. C-F patients, n=12; PtC patients, n=10. 
2.2.5. Select bacterial modules can identify colitis patients.  
We next sought to assess the predictive accuracy of these microbial modules in 
determining a patient’s risk for colitis. Utilizing the recursive partitioning machine-
learning algorithm to form a classification tree based on the 102 modules, samples were 
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successfully classified as from either PtC or C-F patients using the relative abundance of 
polyamine transport system module alone (Fig. 2.8a). Samples with greater than 1% 
relative abundance of the polyamine transport system were binned as Colitis-Free (Fig. 
2.9). Of the PtC patients, 7 samples were appropriately identified while 3 samples were 
misclassified as C-F, resulting in a sensitivity of 70% and specificity of 100% (Fig. 2.8a). 
Performing a leave-one-out cross-validation of the probit regression analysis based on 4 
of the modules associated with C-F patients, we correctly predicted the colitis status for 
10 out of 12 C-F patients and 7 out of 10 PtC patients, at a probability threshold of 50% 
(Fig. 2.8b). This model results in a sensitivity of 70% and specificity of 83%. For this 
regression analysis, we selected the 4 modules associated with resistance to colitis that 
were identified in the Spearman and LEfSe analyses, which include the polyamine 
transport system module and modules involved in the biosynthesis of vitamins riboflavin 
(B2), pantothenate (B5) and thiamine (B1). These modules performed better in 
combination than any individual module (Fig. 2.8c). Taken together, our 4-module 
analysis predicts colitis risk with good accuracy as demonstrated by Receiver Operating 
Characteristic (ROC) curve, for which there are no other known biomarkers presented in 
the literature to use for comparison (Fig. 2.8d) (12, 15). In all, these analytical models 
identify bacterial pathways that may confer resistance to colitis and serve as biomarkers 
for patients at high risk of developing CTLA-4 blockade-induced colitis.   
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Figure 2.8 | Predictive accuracy of bacterial modules to identify patients who develop colitis. a) The 
recursive partitioning algorithm was utilized to construct a classification tree, based on the abundance of 
the polyamine transport module. b) Leave-one-out cross-validation of the probit regression analysis 
predicts the probability of colitis using four modules associated with colitis resistance: polyamine transport 
system, thiamine biosynthesis, riboflavin biosynthesis, and pantothenate biosynthesis. One patient is 
represented per column. Specificity and sensitivity calculated based on a probability threshold of 50%. c) 
The sensitivity and specificity of each module to predict patients’ colitis status by their fecal microbial 
samples was determined using a probability threshold of 50%, as compared to the four-module model. d) 
Receiver Operating Characteristic (ROC) curve of the four-module model predicting colitis risk.  ROC 
curve was created by calculating the True Positive Rate and False Positive Rate for 10,000 thresholds of the 
predicted probability of colitis between 0 and 1. True Positive Rate represents the test sensitivity, calculated 
by: True Positives / (True Positives + False Negatives). False Positive Rate, which is given by 1 minus the 
test specificity, is calculated by: False Positives / (False Positives + True Negatives). Poly, polyamine 
transport system; Thi, thiamine biosynthesis; Ribo, riboflavin biosynthesis; Panto, pantothenate 
biosynthesis. C-F patients, n=12; PtC patients, n=10. 
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 Figure 2.9 | Module abundance of the polyamine transport system. The recursive partitioning algorithm 
estimated colitis status of patient samples based on polyamine transport system abundance alone. Samples 
with a module abundance of >1% were classified as Colitis-Free by this algorithm. C-F patients, n=12; PtC 
patients, n=10. 
2.4. DISCUSSION  
Our study is the first to characterize the intestinal microbiota of patients before the 
development of intestinal inflammation and has identified microbiota-associated 
biomarkers that correlate with protection against CTLA-4 blockade-associated colitis. 
Our finding that members of the Bacteroidetes phylum are enriched in colitis-resistant 
patients is consistent with a proposed immunomodulatory role of these commensal 
bacteria. Bacteroidetes represents one of the major phyla of the human colonic 
microbiota and its members can limit inflammation by stimulating T-regulatory cell 
differentiation (82,83). Following the publication of our work, a second group 
independently verified our finding that higher abundances of Bacteroidetes prior to 
ipilimumab treatment are associated with lower risk of colitis in a French cohort of 
metastatic melanoma patients (99).  
In addition, we show that the presence of microbiota-associated modules for bacterial 
polyamine transport system and the biosynthesis of thiamine, riboflavin and pantothenate 
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can accurately assess a patient’s risk of developing colitis following CTLA-4 blockade. 
The microbiota plays an important role in the endogenous synthesis of water-soluble B 
vitamins and amines which can contribute to mucosal tolerance (100-102). Thiamine and 
riboflavin concentrations are significantly reduced in the blood of patients with Crohn’s 
disease and the levels of bound pantothenate in the colonic mucosa decrease with the 
progression of inflammatory bowel disease (1003,104). An innate-like T-cell population 
known as mucosal-associated invariant T cells are activated in vitro by riboflavin 
metabolites (105,106). These cells accumulate in the inflamed mucosa of Crohn’s Disease 
patients, although it is not yet known if their IL-17-skewed cytokine expression 
exacerbates or limits inflammation. Polyamines, which are small cationic amines that can 
be exported from bacteria cells through the spermidine and putrescine transport system 
(potA, B, C, and D), play an anti-inflammatory role by promoting colonic epithelial cell 
(CEC) proliferation to maintain the epithelial barrier (107). In patients with active colitis, 
levels of orthinine decarboxylase (ODC), the enzyme involved in polyamine synthesis, 
are lower than in control patients, but it remains unclear whether reduced polyamine 
levels contribute to colitis development or progression (108,109). Additional studies are 
required to further explore whether a reduced capacity for microbe-mediated production 
of B vitamins and polyamine transport lowers the threshold for initiation of immune-
mediated colitis.  
As with treatment efficacy, the microbiota may play a role in the development of 
immune-mediated, new-onset colitis in the context of other immunotherapies. 
Identification of biomarkers that predict the risk of developing colitis may help identify 
patients that are particularly susceptible to distinct forms of immunotherapy-induced 
inflammation, such as with CTLA-4 blockade, and may facilitate preemptive treatments.  
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2.4. METHODS 
2.4.1. Study patients and specimen collection. 34 adults analyzed in our study were 
diagnosed with metastatic melanoma and received ipilimumab at Memorial Sloan-
Kettering Cancer Center (MSKCC). Subjects had no previous history of colitis and bowel 
resection and had not received antibiotic treatment in the preceding 2 months. Patients 
were excluded from analysis if the first fecal sample was collected after the onset of 
colitis, if the patient did not receive ipilimumab, or if colitis status was unknown. 
Ipilimumab monotherapy was administered at a dose of 3mg/kg every 3 weeks for up to 4 
doses, with three exceptions. Patients #10 and #15 received vemurafenib before and 
during ipilimumab treatment as part of a clinical trial. Patient #13 was part of a blinded 
clinical trial and received ipilimumab at either 3 mg/kg or 10 mg/kg. A small number of 
patients (Progressed to Colitis, n=2; Colitis-Free, n=3) received additional doses of 
ipilimumab either as part of maintenance treatment (every 3 months) on a clinical study 
or as part of a second course of ipilimumab; however, the colitis cases documented here 
occurred before this additional dosing was administered. Systemic cancer treatment 
administered prior to (n=14) or both before and during (n=2) ipilimumab therapy was 
determined retrospectively upon chart review by a single investigator (MKC).  For 30 
patients, fecal samples were collected from each participant prior to the first 
administration of ipilimumab; for 2 patients who developed gastrointestinal inflammation 
and 2 patients who remained inflammation free, samples were collected after the 
initiation of CTLA-4 blockade, but before onset of colitis. Toxicities were graded 
retrospectively by a single investigator (MKC) based upon chart review using CTCAE, 
version 4.0 and grading on the terms diarrhea and colitis. Patients were assigned a colitis 
score based upon the following: no diarrhea (score 0), grade 1 diarrhea (score 1), grade 2 
diarrhea (score 2), grade 2 diarrhea and/or grade 2 colitis (all 3 cases had both grade 2 
diarrhea and grade 2 colitis) (score 3), grade 3 diarrhea and/or grade 3 colitis (1 case with 
both grade 3 diarrhea and grade 3 colitis) (score 4). All participants provided written 
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consent for specimen collection and analysis under the study protocol approved by the 
MSKCC Institutional Review Board.  
2.4.2. DNA extraction. Each fecal sample was immediately snap-frozen at -80C and 
subsequently subjected to bead beating and phenol chloroform extraction for DNA 
purification. Samples were resuspended in 500 µl of an extraction buffer (200 mM Tris, 
pH 8.0/200 mM NaCl/20 mM EDTA), 200 µl of 20% SDS, 500 µl of 
phenol:chloroform:isoamyl alcohol (24:24:1), and 500 µl of 0.1-mm diameter zirconia/
silica beads (BioSpec Products). For 2 min, cells were lysed by mechanical disruption 
using a bead beater. DNA was extracted in a phenol/chloroform/isoamyl solution twice 
and precipitated with ethanol and sodium acetate. DNA was resuspended in 200 µl of TE 
buffer containing 100ug/ml RNase and further purified using QIAmp Mini Spin Columns 
(Qiagen). After eluting the sample in 100 µl of distilled water, double-stranded DNA was 
quantified.  
2.4.3. 16S rRNA gene amplification and multiparallel sequencing. The V4-V5 region 
of the 16S rRNA gene was amplified and sequenced on the llumina MiSeq platform. For 
each fecal sample, replicate PCR reactions were performed using modified universal 
bacterial primers designed to amplify the V4-V5 16S rRNA region: 563F (59-nnnnnnnn-
NNNNNNNNNNNN-AYTGGGYDTAAAGN G-39) and 926R (59- nnnnnnnn-
NNNNNNNNNNNN-CCGTCAATTYHTTTR AGT-39). Each reaction contained 50 ng 
of purified DNA, 0.2 mM dNTPs, 1.5 uM MgCl2, 1.25 U Platinum TaqDNA poly-
merase, 2.5 µl of 10x PCR buffer, and 0.2 µM of each primer. A unique 12-base Golay 
barcode (Ns) preceded the primers for sample identification after pooling amplicons. One 
to eight additional nucleotides were added before the barcode to offset the sequencing of 
the primers. Cycling conditions were the following: 94 °C for 3 min, followed by 27 
cycles of 94 °C for 50 sec, 51 °C for 30 sec, and 72 °C for 1 min, where the final 
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elongation step was performed at 72 °C for 5 min. Replicate PCRs were combined and 
were subsequently purified using the Qiaquick PCR Purification Kit (Qiagen) and Qiagen 
MinElute PCR Purification Kit. Using the Illumina TruSeq Sample Preparation 
procedure, PCR products were quantified and pooled at equimolar amounts before 
Illumina barcodes and adaptors were ligated on. The completed library was sequenced on 
an Ilumina Miseq platform according to the Illumina recommended protocol.  
2.4.4. Sequence analysis. Sequences were analyzed using mothur version 1.31.1. 
Sequences were aligned using the Silva reference alignment as a template and potentially 
chimeric sequences were eliminated using the UChime algorithm. 5000 sequences per 
patient were selected (mean, 4974; SD, 150) and sequences with a distance-based 
similarity of 97% or greater were grouped into operational taxonomic units (OTUs) using 
the furthest-neighbor algorithm. OTUs were classified using the Greengenes 16S rRNA 
reference database. OTU-based microbial diversity was estimated by calculating two 
diversity indexes, Shannon and Inverse Simpson. OTU-based richness was determined by 
calculating the Chao richness estimate and constructing rarefaction curves. OTUs were 
grouped at different levels of classification (phylum, class, order, family, genus); at each 
level, OTUs that did not have a classification were grouped together by the highest 
available resolution (e.g. at the genus level, an OTU classified as 
p__Bacteroidetes_c__Bacteroidia_ o__Bacteroidales_ f__Barnesiellaceae_unclassifed 
will be grouped as f__Barnesiellaceae_unclassifed). Feature selection of the intestinal 
microbia’s composition was performed on OTUs with an average abundance greater than 
0.01% in either patient group and grouped by phylotype.  
2.4.5. Shotgun sequencing and metabolic pathway reconstruction. Stool samples from 
all 10 Progressed to Colitis (PtC) patients and 12 Colitis-Free (C-F) patients were 
subjected to shotgun sequencing. C-F patient samples were chosen so that the full 
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spectrum of Bacteroidetes phylum abundance was represented. Libraries were 
constructed with Illumina barcodes from the TruSeq DNA Sample Prep kit (Illumina) and 
reagents from KAPA Library Preparation kit (Kapa Biosystems), and then sequenced on 
an Illumina MiSeq platform using 2 × 250 nucleotide paired-end sequencing, according 
to the manufacturer’s instructions. Sequencing reads were converted into relative 
abundances of microbial metabolic modules using HUMAnN, the Human Microbiome 
Project metabolic reconstruction pipeline, and mapped to the Kyoto Encyclopedia of 
Genes and Genomes (KEGG). Relative species abundances were calculated by the 
MetaPhlAn pipeline.  
2.4.6. Statistics. Statistical analyses of intestinal microbiota samples were performed 
using R Statistical Language (v3.1.1) and GraphPad Prism (version 6.0e) software 
packages. Unpaired Mann-Whitney rank sum test (two-tailed) was used for comparisons 
of continuous variables between two groups. Bar plots were used to represent the data’s 
mean at the center values, with error bars to indicate standard deviation. Spearman rank 
correlation tests (two-tailed) were used to find significant correlations between two 
continuous variables. Linear discriminant analysis effect size (LEfSe) was used to 
identify differentially abundant features between classes of samples.  Recursive 
partitioning to form classification trees was performed in R using the packages rpart. 
Generalized linear model (using probit regression and the glm R-function) was 
constructed on all combinations of the following five modules associated with Colitis-
Free patients: Polyamine transport system (M299), Riboflavin biosynthesis (M125), 
Pantothenate biosynthesis (M119), Thiamine biosynthesis (M127) and Biotin 
biosynthesis (M123). Leave-one-out cross-validation was used to compute model 
sensitivity and specificity. The reported model provided the best total sensitivity plus 
specificity. Unadjusted p-values less than 0.05 were considered to be significant for the 
Mann-Whitney rank sum test and Spearman rank correlation tests.  
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CHAPTER THREE 
MICROBIOTA-MEDIATED PROTECTION AGAINST THE ANTIBIOTIC-
RESISTANT GRAM-NEGATIVE PATHOGEN KLEBSIELLA PNEUMONIAE 
3.1. INTRODUCTION   
The rise of antibiotic resistance among bacterial pathogens poses a serious health threat 
(14,110,111). The decreasing number of effective antibiotic treatment options has limited 
our ability to control bacterial infections (112). Members of the family 
Enterobacteriaceae, such as Klebsiella pneumoniae, are among the most concerning 
pathogens, as a growing number produce extended spectrum β- 
lactamase (ESBLs) (113-116). ESBL-producers cause an estimated 26,000 infections and 
1,700 deaths annually and are inhibited only by the carbapenem family of antimicrobials 
(117). As resistant infections require more expensive treatments and longer hospital stays, 
the total economic burden of antibiotic resistance exceeds $20 billion (117,118). This 
clinical picture necessitates the development of novel approaches to treat infectious 
disease. Fortunately, the commensal microbes that colonize the human gut are capable of 
preventing infection caused by antibiotic-resistant pathogens (119). Adoptively 
transferring commensal populations into susceptible hosts offers a promising alternative 
to antimicrobial treatment. However, we have limited knowledge of the precise microbial 
populations that are required to inhibit intestinal colonization by antibiotic-resistant 
proteobacteria.  
Here, we sought to determine which intestinal bacteria provide resistance to the 
antibiotic-resistant gram-negative K. pneumoniae (Kp). We first treated mice with 
different classes of antibiotics to differentially deplete microbial communities from the 
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GI tract. Ampicillin had the longest-lived impact on susceptibility to Kp. The loss of 
Clostridia class members was correlated with higher Kp density. Colonization resistance 
was restored when reconstituting mice with bacteria cultured anaerobically from donors 
with ampicillin-resistant microbiota (ARM). In vitro studies demonstrate that only 
anaerobic bacteria limit Kp growth from ampicillin-sensitive microbiota donors. A 
consortium of human-derived anaerobes, largely of clostridial strains, can resolve Kp 
colonization by 2-4 logs. A human-derived isolate of Blautia producta prevents Kp 
growth ex vivo through acetate production. Further work in the Pamer lab has 
characterized this finding of short-chain fatty acid-induced Kp inhibition in vivo. A 
second commensal was found, Klebsiella oxytoca, that alone could resolve Kp infection 
in our mouse model, mediated through cell contact. Using statistical models, we found 
that certain clostridial OTUs can help predict if Kp colonization resolves over time. 
3.2. RESULTS  
3.2.1 Antibiotics abrogate colonization resistance to low inoculating doses of K. 
pneumoniae.  
Two experimental designs were employed to investigate the role of the intestinal 
microbiota in resolving and preventing Kp colonization (Fig. 3.1a,b). 8-10 week-old 
naïve C57BL/6 mice were treated with oral ampicillin (0.5 g/L) for 3 days and then orally 
challenged with an ampicillin- and carbapenem-resistant Kp bloodstream isolate that 
belongs to the ST258 clade (120) (Fig. 3.1a). We hereby refer to our antibiotic resistant 
isolate as AR-Kp. To first test if the intestinal microbiota is required for colonization 
resistance, antibiotic-treated or untreated mice were inoculated with 105 CFU of AR-Kp 
by oral gavage. Treatment with ampicillin renders mice highly susceptible to AR-Kp 
(Fig. 3.1c). Intestinal expansion is achieved as early as 12 hours post-inoculation (Fig. 
3.1d). Once colonized, AR-Kp dominates the intestinal tract for up to four weeks even in 
the absence of continued oral antibiotic treatment (Fig. 3.1e). Patients who become 
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dominated with AR-Kp are either asymptomatic carriers or acquired it from the hospital 
setting, likely in low numbers from hands of medical staff or surfaces. We therefore 
tested the limiting inoculum dose of AR-Kp that results in high intestinal AR-Kp density. 
AR-Kp expands to a large bacterial load in the GI tract after transferring as few as 10 
CFUs (Fig. 3.1f). For future experiments, 100 CFUs was chosen as our inoculating dose. 
These data indicate that the ampicillin-sensitive component of the intestinal flora is 
necessary and sufficient for providing colonization resistance to small inocula. 
Figure 3.1 | Antibiotics disrupt colonization resistance to low-dose inocula of K. pneumoniae. a) 
Schematic for experiments that test the resolution of AR-Kp colonization. Mice were treated with 
ampicillin 0.5g/L in the drinking water for 3 days, then challenged with AR-Kp (100 CFU/ms unless 
otherwise noted) in 200ul/ms. Mice received a fecal microbiota transplant (FMT) 4 days after Kp 
challenge. If FMT consisted of ampicillin-sensitive bacteria, mice were taken off ampicillin following Kp 
inoculation. b) Schematic for experiments that test the prevention of AR-Kp colonization. Mice were 
pretreated with ampicillin for 3 days as stated in (a). If the FMT was ampicillin-resistant, mice were 
gavaged 3 days after antibiotic initiation. If the FMT was ampicillin-sensitive, an additional 4 rest days 
were given between antibiotic cessation and before FMT reconstitution. c) Untreated mice received no 
antibiotics; those on ampicillin were treated for 3 days. Results are compiled from 2 experiments. d) Mice 
were sacrificed either 12 hours or 8 days after ampicillin administration and CFUs per gram of intestinal 
content were measured by growing PBS-resuspended content on LB plates with 100ug/ml of carbenicillin 
and 50ug/ml neomycin; n=3 per group. e) After a 3-day treatment with ampicillin, mice were either 
continually treated with antibiotics (amp-on) or allowed to recover with untreated water (amp-recov); n=3 
per group. f) Kp was grown to mid-log stage and serially diluted. Mice were orally gavaged at the indicated 
Kp dose in 200ul. ****, p<0.00001.  
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3.2.2. Fecal microbiota transplants (FMT) restore colonization resistance to K. 
pneumoniae.  
To determine whether the reconstitution of a diverse intestinal flora restores colonization 
resistance, complex colonic ampicillin-resistant microbiota (ARM) was adoptively 
transferred to antibiotic-treated mice 3 days prior to AR-Kp inoculation (Fig. 3.1a). ARM 
was derived from a strain of immunocompromised mice in the Pamer lab colony that has 
been treated with amoxicillin for over 10 years. This strategy allows for continuous 
antibiotic treatment without any negative interactions between the antibiotics and 
microbioa. PBS was administered as an FMT control. ARM-recipient mice are fully 
protected from AR-Kp colonization (Fig. 3.2a). To determine whether transplantation of 
complex flora eliminates AR-Kp from the GI tract (Fig. 3.1b), ARM was orally gavaged 
into antibiotic-treated mice that have been colonized for 4 days with AR-Kp. After 4 
weeks, ARM-recipients had nearly a five-log reduction in AR-Kp burden (Fig. 3.2b).  
 
Figure 3.2 | Adoptive transfer of fecal microbiota restores colonization resistance to K. pneumonaie 
that was lost after antibiotic treatment. a) Kp density in fecal content (CFU/g) in mice that received an 
FMT or mock treatment (PBS) prior to challenge (100 CFUs). Results are compiled from 4 experiments. 
Kp density in mice that received an FMT or mock treatment (PBS) before Kp challenge (100 CFUs); in b), 
FMT was ampicillin-resistant (ARM); in c), FMT was ampicillin-sensitive (ASM). Results are compiled 
from 2 experiments for b and c. p<0.0001, ****, p<0.00001. 
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Previous work in the Pamer lab has compared the composition of ARM maintained in our 
MyD88-/- mouse colony to naïve C57BL/6 mice and noted distinct though overlapping 
bacterial communities (30). We therefore tested the efficacy of an FMT from ampicillin-
sensitive microbiota (ASM) derived from age-matched naïve C57BL/6 mice. For such 
experiments, we removed ampicillin pressure following AR-Kp inoculation. The kinetics 
of AR-Kp resolution were similar between the two FMT donors as both partially 
eliminate AR-Kp from the gut by day 7 (Fig. 3.2c). Taken together, these data indicate 
that intestinal microbiota protects against gram-negative colonization and restores 
resistance following fecal bacteriotherapy from unique donors.  
3.2.3. Different classes of antibiotics induce distinct alternations to the intestinal 
microbiota composition that have lasting consequences for K. pneumoniae 
susceptibility. 
Antimicrobials disrupt the intestinal microbiota in distinct ways by acting on different 
bacterial targets. The resulting changes to the microbiota’s composition leaves patients at 
variable risk for AR-Kp expansion. We characterized the effect of short-term antibiotic 
treatment on the susceptibility to AR-Kp colonization. Mice were treated for 3 days with 
either ampicillin (Fig. 3.3a), metronidazole (Fig. 3.3b), or vancomycin (Fig. 3.3c) in the 
drinking water. Clindamycin was administered once via intraperitoneal injection (Fig. 
3.3d). The microbiota was left to recover prior to AR-Kp challenge for various number of 
days post antibiotic cessation (indicated on the x-axis). Ampicillin had the most profound 
change, attenuating colonization resistance for up to 14 days. A similar long-lived effect 
was seen in clindamycin, a broad-spectrum antibiotic active against obligate anaerobes, 
but only in one mouse tested. Metronidazole and vancomycin had brief effects in our 
hands, although work from other Pamer lab members has shown AR-Kp susceptibility for 
longer durations with vancomycin (121). Given that ampicillin treatment resulted in the 
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most variance in resistance recovery, we compared the structure of the microbiota’s 
composition prior to AR-Kp challenge from one experiment depicted in Fig. 3a. OTUs 
were grouped at the genus level and those genera with a mean abundance of >1% were 
plotted. The loss of Clostridium genus is associated with increased AR-Kp susceptibility 
(Fig. 3.3e). 3 of the 4 operational taxonomic units (OTUs) negatively correlated with AR-
Kp levels by spearman were assigned to the Clostridium disporicum species (ρ < -0.7). 
Thus antibiotic-induced shifts in commensal microbial populations correspond to variable 
recovery of resistance.  
 
Figure 3.3 | Differential impact of antibiotics on intestinal K. pneumonaie susceptibility. Mice were 
treated with the indicated antibiotics for 3 days: a) ampicillin at 0.5g/L, b) metronidazole at 1g/L, and c) 
vancomycin at 0.5h/L. Results in a) are compiled from two experiments. d) Clindamycin was administered 
in one 200 μg dose via intraperitoneal injection. Mice were challenged with 100 Kp CFUs by oral gavage 
on the indicated days after antibiotic cessation. Kp burden was measured by plating fecal content collected 
24 hours after challenge. e) OTUs on the day prior to Kp inoculation are plotted in mice that had been 
allowed to recover following ampicillin administration. OTUs with >10 reads total and an average relative 
abundance >0.02% (across multiple experiments) were binned at the genus level and genera with a mean 
>1% were plotted. Kp density in CFU/g content was measured 24hrs after challenge, and samples are 
ordered in the heatmap by Kp burden (converted to natural log). OTUs, operational taxonomic units.  
!35
3.2.4. Obligate anaerobes protect against intestinal K. pneumoniae infection. 
In an alternative approach to determining which subsets of the complex intestinal 
microbiota are required for resistance, colonic ARM was cultured on blood-agar plates at 
37 C in either aerobic or anaerobic conditions for 3 days. Colonies were resuspended in 
sterile PBS and transplanted into antibiotic-treated mice. A single transfer of the 
anaerobic and aerobic fraction of ARM protected against AR-Kp challenge (Fig. 3.4a). A 
complementary experiment was performed ex vivo by culturing AR-Kp in ASM cecal 
content anaerobically and aerobically. Only anaerobes prevented AR-Kp growth (Fig. 
3.4b). We therefore focused on adoptively transferring smaller fractions of the anaerobic 
microbiota. We performed serial dilutions of anerobically-grown ARM as our bacterial 
consortium transplant (BCT) inoculum. We transferred roughly 1000, 100 and 10 isolates 
at 10-5, 10-6, 10-7 dilutions respectively. The 2 higher dilutions conferred a 3-4 log 
reduction in AR-Kp colonization, while the lowest failed to protect (Fig. 3.4c). These 
data suggested that a discrete set of bacterial species could recover colonization 
resistance via BCT. We then turned to a human-derived 17-strain collection of anaerobic 
Clostridia species (122,123). We spiked roughly 108 CFUs of midlog cultures of selected 
Clostridia isolates into antibiotic-treated cecal content with 100 CFU of AR-Kp. After 24-
hr ex vivo co-culture, one isolate in our screen, Blautia producta, inhibited AR-Kp growth 
nearly as well as untreated cecal content (Fig. 3.4d).   
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Figure 3.4 | Obligate anaerobes in vivo and ex vivo inhibit K. pneumoniae growth. a) Fecal pellets from 
an ARM donor were resuspended in either normal or reduced PBS to roughly 50mg/ml and cultured on 
blood agar plates (BAPs) for 3 days at 37C in either aerobic or anaerobic conditions, respectively. In a third 
condition, the resuspended content was treated in 3% solution of chloroform at 225 rpm for 1 hour and then 
plated on reduced BAPs. Bacterial lawns were collected by scraping each BAP and resuspended in PBS. 
Bacterial solutions were transplanted at 200ul per mouse. On the day of transplant, additional ARM pellets 
were resuspended in PBS – one aliquot of the fecal suspension was kept on ice as an FMT control, a second 
aliquot was autoclaved for 30min. n=3 mice per group. b) Cecal content from untreated and 3-day 
ampicillin-treated mice were resuspended in PBS to roughly 250mg/ml and 200ul/ well was added in a 96-
well plate. 100 Kp CFUs were co-cultured per well (20ul). c) Fecal pellets were harvested as described in 
(a) and were serially plated on reduced BAPs. Indicated dilutions were transplanted in 200ul into pretreated 
mice that then received a 100-CFU Kp challenge. n=3 mice per group. d) 108 CFUs of anaerobic strains in 
midlog cultures were added to wells (100ul) with ~250mg/ml antibiotic-treated cecal content (100ul) and 
co-cultured with 100 Kp CFUs (20ul). Ex vivo conditions were cultured in triplicates. Ci, Clostridium 
indolis; Ch, Clostridium hathewayi; Bp, Blautia producta. 
3.2.5. Short-chain fatty acids suppresses K. pneumoniae growth.  
Over 107 CFU of Blautia producta is required to fully suppress AR-Kp growth in vitro 
(Fig. 3.5a). To determine if this inhibition was mediated by cell contact or a bacterial 
product, we grew AR-Kp in filtered culture media from an overnight culture of Blautia 
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producta (Bp-FCM). Bp-FCM inhibited AR-Kp growth, however this affect was diluted 
when adding more media than a 5:1 ratio of Bp-FCM to BHI (Fig. 3.5b). Bp-FCM is 
acidic at a pH 5.2. Reducing the neutral pH of BHI to 5.2 with HCl did not inhibit AR-Kp 
growth in vitro (Fig. 3.5c). Thus, the acidic environment of the Bp-FCM alone does not 
suppress AR-Kp. Normalizing the Bp-FCM pH to 7 with NaHCO3, however, abrogated 
its inhibitory effect (Fig. 3.5c). This pH-dependent growth inhibition suggested that 
Blautia producta operates through a weak acidic metabolite such as short-chain fatty 
acids. Of the isolates in the 17-strain collection, Blautia producta was the highest acetate 
producer (123). We found that 25mM of acetic acid impacts AR-Kp growth to the same 
degree as the Bp-FCM (Fig. 3.5d). This concentration is in range with the 50-100 mM 
physiological levels of total SCFAs in the colonic lumen of patients and rodents, with 
60:20:20 ratio of acetate, butyrate, priopionate (124,125). We further demonstrated that 
the acetic acid, and not the anion acetate, mediates this suppression. Holding the 
concentration of acetate constant at 100mM, we changed the pH and thus acetic acid 
levels. A drop from 36mM to 5.75mM of acetic acid abolished its inhibitory effect (Fig. 
3.5e). This finding fits with our knowledge that acetic acid in its protonated form can 
cross the hydrophobic cell membrane and then dissociate to drop the intracellular pH 
(61). Glycine was not able to rescue acetate-induced growth inhibition (5-50mM tested; 
data not shown). Additional work in the Pamer lab has extended this finding in vivo to 
show that ~20mM of commensal-derived acetate inhibits AR-Kp growth in the GI tract.  
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 Figure 3.5 | Blautia producta suppresses K. pneumoniae growth in vitro through a metabolite that 
operates by a pH-dependent mechanism. a) A midlog culture of Blautia producta (5x108 CFU/ml) was 
serially diluted and co-cultured with 100 Kp CFUs in vitro (50ul of BHI in 220ul total). Filtered culture 
media (FCM) was obtained by filtering 4ml of an overnight midlog Blautia producta culture at 0.22um. 
BHI media was added to Bp-FCM at the ratios indicated in b) and in 10:1 (FCM:BHI) in c). In both b) and 
c), the BHI control is 1:10 media in PBS; total volume is 200ul/well. 100 Kp CFUs was cultured in the 
indicated concentrations of acetic acid/acetate (mM) in d) and e) with BHI in 2ml total.  
3.2.6. Klebisella oxytoca, a member of the enteric microbiota, inhibits K. pneumoniae 
colonization through a cell contact-mediated mechanism.  
In our fractionation experiments, we found that the aerobic compartment of the ARM, but 
not ASM, could prevent AR-Kp colonization in vivo. Dilutions as low as 10-5 of ARM, 
which resulted in transplanting aerobic 14 colonies, rescued resistance post-antibiotic 
treatment in vivo (Fig. 3.6a). By Sanger-sequencing the full-length 16S rRNA gene, we 
!39
identified 13 isolates as Enterococcus casseliflavus and 1 that belonged to the Klebsiella 
genus, K. oxytoca. 2x108 CFUs of bacteria in total was adoptively transferred into 
ampicillin-treated mice for three inocula: the 13 E. casseliflavus isolates, 1 K. oxytoca 
strain or the 14 isolates together. Only the groups that received the K. oxytoca isolate 
resisted AR-Kp challenge (Fig. 3.6b). In vivo and in vitro, 108 CFUs of K. oxytoca 
inhibited AR-Kp growth (Fig. 3.6c). As with Blautia producta, we tested if this Klebsiella 
strain produced a metabolite that had inhibitory effect. AR-Kp grew as well in LB as K. 
oxytoca-FCM, even without the addition of fresh media (Fig. 3.6d). Thus, K. oxytoca 
does not deplete AR-Kp of its essential nutrients, making in vivo nutrient competition a 
less likely mechanism. Taken together, these data indicate that K. oxytoca suppresses AR-
Kp growth in cell-contact dependent manner. 
 
Figure 3.6 | A related species Klebisella oxytoca can eradicate K. pneumoniae from the GI tract. a) 
Fecal pellets were harvested from an ARM donor and were serially plated on BAPs grown at 37C 
aerobically. Indicated dilutions were transplanted in 200ul into pretreated mice, which then received a 100 
Kp CFU challenge. n=3 mice per group. b) 14 aerobic strains were cultured in 6ml BHI for 5.5hrs to 
roughly 109 CFU/ml. 2x108 CFUs in 200ul per BCT were adoptively transferred to pretreated mice. c) A 
midlog culture of K. oxytoca (2x109 CFU/ml) was serially diluted and co-cultured with 100 Kp CFUs in 
vitro (50ul of BHI in 200ul total). d) 4ml of midlog cultures of either Kp or K. oxytoca were filtered at 
0.22um. 100 CFUs of Kp was added to the 2ml of Kp-FCM and Ko-FCM and grown for 5hrs at 37C at 
255rpm.  
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3.2.7. Clostridial species are associated with the prevention of K. pneumoniae 
colonization.  
To identify commensals correlated with prevention of AR-Kp colonization, the intestinal 
microbiota of a total 318 mice were perturbed prior to AR-Kp challenge using a variety 
of experimental protocols, such as multi-drug antibiotic cocktails and different antibiotic 
doses with or without bacterial reconstitution. The heatmap depicts OTU relative 
abundances over time  for these mice (Fig. 3.7a). The samples are ranked according to 
AR-Kp burden measured by the next sample collected for the same mouse, between 1-7 
days later.  
Figure 3.7 | Members of the Clostridia class are correlated with colonization resistance. A heatmap of 
16S sequencing samples from mice (n=318) from prevention experiments. a) OTUs were grouped at the 
genus level, and samples were ordered by the Kp burden measured at the following timepoint (converted to 
natural log). Each column represents a mouse. Mice are ordered by Kp density 1-7days post-challenge. b) 
16S relative abundances of the major OTU classified as Klebsiella pneumonaie is plotted against the Kp 
density within the same sample, measured in over 2000 samples across 24 experiments. c) The 20 of the 
most negatively correlated OTUs (/66 OTUs total) in the spearman analysis, with correlation of <-0.3, are 
plotted. d) Genera with 3 or more OTUs found significant in the spearman analysis are represented in the 
table.  
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The relative abundance of the major OTU classified as K. pneumoniae correlates well 
with the AR-Kp levels measured within that same sample, indicating that OTU relative 
abundances accurately reflect bacterial density in our experiments (Fig. 3.7b). 
Performing a spearman analysis on this dataset, we found 66 OTUs that were 
significantly negatively correlated with AR-Kp density (Fig. 3.7c). We grouped all 
significant OTUs at the genus level and found that Clostridium species were the most 
represented, with 20 OTUs (30%) assigned to the genus. Our data demonstrates that 
higher abundances of clostridial commensals are strongly correlated with suppressed 
growth states of AR-Kp in vivo. 
3.2.8. Clostridial commensals are correlated with the rescue of colonization 
resistance.  
We then asked if resolving high-density Klebsiella colonization requires a different, 
precise set of commensals that can flourish despite AR-Kp overgrowth. To address this, 
we first performed a series of resolution experiments (Fig. 3.1b) to test the 
reproducibility of our ASM-FMT findings with other K. pneumoniae strains. Using our 
MH258 AR-Kp strain as a control, we found similar kinetics of elimination with other 
carpanenamase-producing (CP) strains (Fig. 3.8a) and non-CP Kp isolates (Fig. 3.8b) of 
K. pneumoniae. We then transplanted the 17-strain human-derived Clostridia consortium 
into MH258 Kp-colonized mice, using Lactobacillus johnonsii as a BCT control. 
Although the dynamics were slowed, 2 out of the 4 Clostridia-only recipients eliminated 
AR-Kp as well as an FMT (Fig. 3.8c). We tested K. oxytoca’s capacity to resolve AR-Kp 
from the GI tract. While also delayed, the K. oxytoca-transferred mice has reached similar 
low densities of AR-Kp as the FMT recipients by day 28 (Fig. 3.8d). 
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Figure 3.8 | The kinetics of K. pneumoniae clearance from the intestine. FMTs derived from ASM 
donors were transplanted into antibiotic-treated mice pre-colonized with either a) carpanenamase-
producing (CP) or b) non-carpanenamase-producing (non-CP) strains. MLST, wzi and K typing for these 
isolates are provided in the Methods. 1 FMT dose was administered. c) 1-10x107 CFUs in total of 17 
clostridial strains were adoptively transferred into Kp-colonized mice in 1 dose. 2x106 CFUs of 
lactobacillus johnsonii served as a BCT control. n=3-4 mice per group. d) Roughly 108 CFUs of K. oxytoca 
were gavaged into Kp-colonized mice. n=3 mice per group. Kp burden was monitored by plating fecal 
pellets on the indicated days post-transplant. 
Using this 16S sequencing data, we leveraged the time-series nature of these resolution 
experiments and built models to determine which bacteria at earlier timepoints were 
predictive of AR-Kp density on the final experimental day (our target variable). In order 
to include 96 mice across 5 experiments in the same model, we grouped samples at a 
range of timepoints: i) day 0, ii) days 1-3 and ii) days 5-10 days relative to transplant 
(Fig. 3.9a). Since the mice had been pre-colonized with Klebsiella, we could measure 
AR-Kp levels (CFU/g) in each sample, which we multiplied by the relative abundance of 
the Kp OTU to determine the total bacterial density per sample. We then calculated 
absolute abundance of each OTU in the same sample, which we used in our model 
instead of relative abundances. The independent variables used were therefore the 
absolute abundances of OTUs on days prior to the last experiment timepoint (e.g. 
OTU1_day0, OTU1_day1, OTU2_day0, OTU2_day1). Given the smaller number of 
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observations (i.e. mice) relative the large extent of features (i.e. OTU absolute 
abundances per day), we performed 10-fold cross-validation to minimize overfitting. 
Lasso regression and random forest classification algorithms were employed. For the 
random forest model, mice were assigned to 1 of 3 groups based on their last measured 
AR-Kp density using k-means clustering (k=3). 3 clusters were selected by visually 
examining the AR-Kp CFU/g distribution. OTUs that were kept in the models were 
ranked by either their coefficient (lasso regression) or feature importance (random forest); 
all OTUs that remained in the models were considered significant.  
 
Figure 3.9 | Select bacterial species are predicted to resolve K. pneumoniae infection. a) Mice (n=96) 
from 5 experiments were pre-colonized with Kp and transplanted with an FMT or bacterial consortium. The 
red line indicates the median Kp CFU/g while the shaded area represents 2 STDs. The absolute abundances 
of OTUs on days 0, 1-3 and 5-10 were used as independent features in our models (b, c). b) Significant 
features in lasso regression are plotted with respect to their coefficients. The right side of the figure 
indicates the day post-transplant that a given feature was significant at. c) OTUs that were significant in the 
random forest model were grouped at the genus level. Genera with 2 or more OTUs assigned are shown.   
The density of AR-Kp in 96 reconstituted mice is plotted over time (Fig. 3.9a). The lasso 
regression analysis identified K. oxtyoca and Blautia producta as OTUs strongly 
associated with Kp clearance, complementing our in vitro experiments (Fig. 3.9b). The 
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most significant predictor of AR-Kp density, Olsenella profusa, could be detected by 1-3 
days post-reconstitution. In the random forest model, 27 OTUs were important predictors, 
of which 6 were clostridial OTUs (Clostridium scindens, lavalense, innocuum and 
algidixylanolyticum), making the Clostridium genus the most represented. The 
Clostridium genus contributed 18% to the total feature importance of the random forest 
model.  
3.2.9. Obligate anaerobes are predictive of changes in intestinal K. pneumoniae 
colonization density in allo-HSCT patients.  
Allo-HSCT patients experience large shifts in their microbiota composition due to 
frequent antibiotic therapy given their immunocompromised status. Stool samples were 
collected over the course of their hospitalization and stored in a fecal biobank. The 
majority of patients had no detectable levels of Kp by 16S rRNA sequencing (Fig. 3.10a). 
Most patient samples were acquired within 7 days of each other, allowing us to 
characterize short-term compositional dynamics (Fig. 3.10b). Most patients did not 
experience large shifts in rate of Kp (Fig. 3.10c). A PCA on the first sample per patient 
collected did not reveal obvious groupings of patients susceptible to high density Kp 
colonization (Fig. 3.10d). We therefore applied our time-series random forest model to 
identify intestinal bacterial species that may be implicated in Kp resistance in human 
hosts. The log change in Kp levels per day between pairs of consecutive patient samples 
collected in a 7-day or shorter timeframe were used as our dependent variable. Target 
variables were binned into 2 levels for the random forest classifier and coded 1 if there 
was a ≥0 log change between samples per day and a 0 was assigned to targets with <0 log 
change. The model’s features were the relative abundances of OTUs measured on the first 
sample of the pair. The model determined that the initial levels of Kp as well as 
Clostridia, Blautia producta, and Faecalibacterium prausnitzii were important predictors 
of the change in intestinal Kp density seen in allo-HSCT patients (Fig. 3.10e).   
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Figure 3.10 | Modeling Kp resolution in allo-HSCT patients. Paired samples (n=650) taken from allo-
HSCT patients were compared. a) The distribution of Kp relative abundances in 389 allo-HSCT patients 
was plotted in natural log. b) The days between all possible pairs of samples are shown. Paired samples 
used in the model had to be collected within <7 days of each other. c) The relative abundances of OTUs 
from the earlier sample were used as features to predict the log Kp change per day (target variable). The 
distribution of the log change in Kp per day is plotted. d) PCA was performed on the first sample from each 
patient. 3 clusters were detected. The distribution of the log change in Kp (relative to the second sample 
from each patient) were broken down by the 3 clusters (k-means clustering, n=3). e) A random forest model 
was constructed using the OTU relative abundances on the first sample of the pair to predict the level of Kp 
log change. Target variables were binned into 2 levels for the classifier and coded 1 if 0 log change between 
samples per day (a 0 was assigned to targets with <0 log change).   
3.3. DISCUSSION.  
Microbiome research utilizes deep 16S rRNA gene sequencing to profile bacterial 
communities of the gut and to predict candidate commensals that confer colonization 
resistance in time-series microbiota-reconstitution experiments. Ecological modeling of 
the microbiota using 16S sequencing data has accurately predicted fluctuations in the 
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composition of the microbiota following clindamycin administration and C. difficile 
challenge, and identified commensal bacteria that could inhibit C. difficile colonization 
(72,126). Here, we employed high throughput sequencing and in vivo adoptive transfer 
experiments to demonstrate the efficacy of bacteriotherapy in clearing intestinal K. 
pneumonaie colonization and to correlate obligate anaerobic commensals from the 
Clostridia class with resistance.  
How these findings are best translated to treating at-risk patients has yet to be 
determined. In a promising phase 1b trial, orally administered capsules of 50 human-
derived live Firmicutes spores prevented recurrent C. difficile infection, while the phase 
II clinical study found no efficacy (127,128). A key question facing the translation of 
optimal bacterial combinations into patient therapy is what is required for a high 
transplantation efficacy. The study that defined a minimal consortium for VRE in mice 
highlights this challenge (30). Successful colonization of B. producta in ampicillin-
treated mice required the adoptive transfer of three additional commensals. B. sartorii 
and P. distasonis inactivate ampicillin through the production of beta-lactamase, which 
was critical for ampicillin-sensitive isolates’ survival in the GI tract, while C. bolteae 
supported B. producta’s engraftment through an unknown mechanism (30). Modulating 
the local gut environment through drug inactivation with probiotics is of particular 
importance for preventing VRE colonization in patients currently receiving antibiotics 
(129). Probiotic commensals can limit pathogen colonization in the gut by mitigating the 
disruptive effects of antibiotics to begin with. A Bacteroides thetaiotaomicron strain that 
produces a cephalosporinase has been shown to prevent intestinal VRE outgrowth by 
inactivating ceftriaxone and thus minimizing any significant changes to the microbiota 
(130). Further work is therefore required to identify the precise combination of isolates 
using in vivo mouse models that can successfully engraft and broadly confer resistance to 
K. pneumoniae-infected hosts.  
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Another open question is whether a protective microbial consortium should be tailored to 
individual patients, and if so, how to scale such a design. Given the falling costs of deep 
sequencing, profiling patients’ microbiota may occur regularly in clinical practice. 
Patients with different degrees of immune system impairment and treatment histories 
may benefit from personalized alterations to the minimally defined protective 
consortium. For example, patients who recently received antibiotics may be deficient in 
nutrients that resistance-mediating bacteria require to survive in the gut, necessitating 
additional isolates to support successful engraftment. Mouse models would not be a 
scalable approach to test these individual modifications. In this era of deep sequencing, 
we can potentially integrate diet, treatment regimens, and gut microbiome data to build 
algorithms that can assess a patient’s risk of colonization by antibiotic-resistant pathogens 
and can optimize probiotic combinations. Incorporating information on microbiome 
composition and function improved predictions of individuals’ glycemic response 
following a meal and helped design dietary interventions for better glycemic control 
(131). Such data-driven approaches may help tailor preclinical findings to individual 
patients at scale to successfully mitigate their susceptibility to pathogen colonization. 
3.4. MATERIALS AND METHODS.  
3.4.1. Mouse husbandry and in vivo challenge experiments. in vivo experiments were 
performed in compliance with Memorial Sloan Kettering’s institutional guidelines and 
were approved by its Institutional Animal Care and Use Committee. 8-10 week old wild-
type female C57BL/6 mice were purchased from the Jackson Laboratories and housed in 
sterile cages with irradiated feed and acidified water. Mice were treated with ampicillin 
0.5g/L in the drinking water for 3 days before Kp challenge and were singly housed at the 
time of inoculation. Kp density was quantified by resuspending fecal pellets in 1ml PBS 
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and plating serial dilutions on Luria-Bertani (LB) agar plates supplemented with 50 µg/
ml neomycin (Sigma-Aldrich) and 100 µg/ml carbenicillin (LabScientific). Plates were 
incubated aerobically for at 37°C. Mice were maintained on ampicillin water for the 
duration of the experiment; if an ampicillin-sensitive FMT or BCT was gavaged, mice 
were taken off ampicillin and rested for 4 days before transplant.   
3.4.2. K. pneumoniae isolates and culture. 5ml LB media was inoculated with frozen 
stock of the MH258 isolate overnight and the next day a 1:20ml diluted culture was 
grown for 2.5hr at 225rpm at 37°C to midlog phase (~OD 0.6 at ~5x108 CFU/ml). Kp 
was serially diluted in PBS to 5x102 CFU/ml to inoculate mice with 100 colony-forming 
units (CFUs) in 200ul/ms by oral gavage. A concentration of 5x103 CFU/ml was obtained 
in order to add 100 CFUs to 96-wells for in vitro and ex vivo co-culture. The table below 
details the MLST, wzi and K type for each K. pneumomiae strain used (116).   
3.4.3. Bacterial culture and isolation. Fecal pellets from MyD88-/- donor mice were 
resuspended in reduced PBS at 20-50mg/ml to serve as ARM-FMTs. ASM-FMTs were 
derived from the cecal content of naïve untreated wild-type female C57BL/6 mice. A 
Isolate Figures Carpanenamase MLST wzi type K type
MH258 All + ST258 wzi-54 ST258 cps2
43309 3.8a + ST11 wzi-177 non-K-type
43303 3.8a + ST11 K24
32192 3.8a + ST258 cps1 K41 
38544 3.8a + ST258 cps3 K57
MH189 3.8b - ST189 wzi-99 K31
MH1867 3.8b - ST11 wzi-177 non-K-type
MH225 3.8b - ST225 wzi-59 K3
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single 200ul dose was adoptively transferred in Kp-colonized or ampicillin-pretreated 
mice with the exception of one experiment (which tested the efficacy of 1, 2 and 3 
sequential FMT doses to clear Kp). To prepare bacterial inocula from diluted intestinal 
content, fecal pellets were resuspended in PBS and aliquoted onto reduced BAPs for 
anaerobic culture and nonreduced BAPs to aerobic growth. Dilution cultures were 
incubated for 3 days at 37°C and scraped into PBS prior to transplant. 15% glycerol 
cultures were stored at -80°C. Individual colonies were restreaked and the16S rRNA gene 
was amplified for each isolate by colony PCR. The resulting PCR product was Sanger 
sequenced with primers that spanned the full 16S gene and classified by BLAST. To 
culture anaerobic isolates for ex vivo co-culture or transplant, 5ml of reduced BHI 
supplemented with 5g of yeast-5g and 1% cysteine (BHI+) was inoculated with frozen 
stocks of anaerobic isolates and grown statically overnight at 37°C. The next day, a 1:20 
diluted culture was incubated statically for 6 hours and 150-200ul were added to 96wells 
for co-culture with Kp. 4ml of the midlog Blautia producta (Bp) liquid culture was 
filtered at 0.22um and added to 96well plates at different ratios with BHI+.  
3.4.4. in vivo and ex vivo growth inhibition assays. Fecal content was resuspended in 
PBS to 50mg/ml and 100-300mg/ml for cecal content. Roughly 108 CFUs of individual 
isolate were added to 96well plates with antibiotic-treated cecal content. Kp growth was 
measured 24hrs after co-culture by plating on selective media. To test growth suppression 
by acetate, stocks were made in 25ml for glacial acetic acid (1M, 0.364M) and sodium 
acetate (anhydrous) (2.75M, 1M). For 1M acetic acid, 1ml sodium acetate (2.75M) and 
1ml glacial acetic acid (1M) was added to 8ml BHI+ to obtain pH 5.2 and serial dilutions 
performed. For 1M sodium acetate, 1ml sodium acetate (1M) and 1ml glacial acetic acid 
(0.364M) was added to 8ml BHI+ to obtain pH 5.2 and serial dilutions performed. In 
vitro cultures with acetate were performed in total 2ml.  
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3.4.5. DNA extraction and 16s rRNA gene sequencing. DNA from intestinal content 
was extracted using the phenol-chloroform extraction method with with bead beating and 
purified with a Qiagen QiaAmp kit. The V4-V5 region of the 16S rRNA gene was 
amplified and PCR products were quantified and pooled at equimolar amounts before 
Illumina barcodes and adaptors were ligated on using the Illumina TruSeq Sample 
Preparation protocol. The completed library was sequenced on an Illumina Miseq 
platform by 2x250bp paired-end reads following the Illumina recommended procedures. 
The 16S paired-end reads were merged and demultiplexed. The UPARSE pipeline was 
used to perform error filtering, using maximum expected error (Emax = 1), group 
sequences into operational taxonomic units (OTUs) of 97% distance-based similarity and 
identify and remove potential chimeric sequences, using both de novo and reference-
based methods. OTUs were classified by BLAST.  
3.4.6. Sequence-based analyses. Sequences were analyzed using a custom Python script 
to convert OTU reads to relative abundances and convert samples to panel data for each 
experiment. Samples had an average of 25500 reads. OTUs with an average relative 
abundance >0.02% (across multiple experiments) met our thresholds. Spearman analyses 
were performed using the stats module in the scipy package and p-values were corrected 
for multiple hypothesis by the Bonferroni-Hochberg procedure. Lasso, ridge and elastic 
net regressions were performed with the sklearn linear model module and the random 
forest classifier with the sklearn ensemble module. The cluster module and 
decomposition modules in sklearn package were used for kmeans clustering and PCA.  
!51
CHAPTER FOUR 
THE EVOLUTION OF VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM 
WITHIN THE GASTROINTESTINAL TRACT 
4.1. INTRODUCTION    
Enterococci are an intestinal commensal as well as leading nosocomial pathogen, 
particularly in the immunocompromised. Vancomycin-resistant Enterococci (VRE) can 
colonize and rapidly expand in patients whose intestinal microbiota has been perturbed 
by antibiotics. Intestinal VRE colonization greatly increases a patient’s risk for 
bloodstream infection, during which VRE can acquire resistance in vivo to antibiotic 
therapy (16,132). Increasingly, epidemiological studies have used single nucleotide 
polymorphisms (SNPs) to track antibiotic-resistant infections in the hospital. However, 
the rapidity of SNP accumulation and its stability over time have not been carefully 
characterized in VRE as it expands the GI tract. Bacterial evolution has generally been 
studied in vitro, documenting a rapid rate of mutations (133). By characterizing the 
temporal dynamics of intestinal VRE evolution, we can shed light on within-host VRE 
diversity and complexity that may confound epidemiological studies.  
Here, we seek to characterize how VRE adapts and diversifies in the GI tract of a 
colonized patient in response to selective pressures from antibiotics and inflammation in 
the gut. We first employed a culture-dependent, longitudinal approach by isolating 
individual VRE colonies at multiple timepoints from five colonized patients. Using high-
throughput whole-genome sequencing, we identify single nucleotide polymorphisms 
(SNPs) to determine the clonal relatedness of VRE in the gut of individual patients over 
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time. We have found that patients can harbor enterococci from multiple sequence types, 
and that there is variability in the number of SNPs per isolate found at any timepoint 
within individual patients. To understand how an individual bacterium evolves in the gut 
from the onset of colonization, we inoculated a mouse with a single VRE CFU and found 
a linear rate of de novo SNP accumulation in our isolates. Combining metagenomic 
shotgun data to our analysis, we obtained a better estimate of the number of mutations 
acquired in a complex bacterial population. We detect hundreds of SNPs that evolve 
rapidly at around three weeks post-colonization. After this rapid evolution, we estimated 
that four subclades of E. faecium exist in stable proportions. A nonsynomous SNP in the 
catalytic domain of the penicillin-binding protein 5 (pbp5) persists at 100% frequency. 
Reperforming this low-inoculum experiment with a different E. faecium strain, we 
detected 3 nonsynomous pbp5 SNPs that changed their frequencies within the intestinal 
VRE population in a pattern that indicates clonal interference. Our results indicate that 
VRE can rapidly adapt within the GI tract in response to selective antibiotic pressure and 
that such diversity is preserved over time.  
4.2. RESULTS  
4.2.1. Genomic diversity of E. faecium in the gut of an individual patient. 
We first characterized the cross-sectional diversity of vancomycin-resistant E. faecium 
(VREfm) in an allo-HSCT patient, herein identified as pt110 (Fig. 4.1a). The patient was 
initially colonized at <10% relative abundance six days prior to bone marrow 
transplantation, after which VREfm expanded and remained in the gut at high densities. A 
single isolate was cultured from three samples taken at day -6, 1, and 8. VREfm isolates 
were subjected to whole-genome sequencing and aligned using breseq to a reference built 
from an isolate isolated from this same patient to call SNPs. Surprisingly, unique SNP 
patterns were seen at each day examined (Fig. 4.1b).  
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Figure 4.1 | Within-host diversity of a single allo-HSCT patient at MSKCC within and across time. a) 
The relative abundances of OTUs measured by 16S rRNA sequencing and grouped at the order level are 
shown for 4 stool samples collected. Days are relative to BMT. b) Lollipops indicate the presence of a SNP 
along the chromosome for 3 VREfm isolates taken on day -6, 1 and 8. c) The SNP densities for 10 isolates 
cultured from day -6 are plotted. SNPs are grouped at 1000-bp intervals along the chromosomal and 
number of SNPs per bin are reported in log-based 10. d) Barplots of the number of SNPs per isolate on 
days -6, 1 and 8. Boxes represent the interquartile range and the stems denote the minimum and maximum. 
e) A maximum-likelihood tree of the MLST 412 isolates cultured across day -6, 1 and 8 based on SNPs in 
the core genomes using the ASC GTR-GAMMA model in RAxML (optimized for <50 genomes). Branch 
length values are the mean expected rates of substitution per site 
To clarify the relatedness of these VREfm strains, we deeply sampled the initial day -6 
timepoint by culturing 10 isolates. Two coexisting lineages were found (Fig. 4.1c), 
revealing even greater diversity than what was observed with the three analyzed genomes 
(Fig. 4.1b). Each bar represents an isolate, where the x-axis indicates the position along 
the chromosome and the y-axis represents the number of SNPs detected (log-based 10) at 
1000-bp intervals against the reference (typed MLST 412) (Fig. 1c). Isolates 2, 4, and 6 
are over 6000 SNP differences from the reference and were typed as MLST 736.  
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We then looked at timepoints following the expansion of VREfm within the gut of this 
patient. At day 8, when VREfm reached over 99% of the intestinal abundance, we 
cultured a set of 10 isolates in total and found a slight increase in the number of SNPs 
accumulated over time (Fig. 4.1d). However, variants detected in earliest timepoint were 
still present. A maximum likelihood tree of the MLST 412 sublineage isolates, based on 
SNPs that appeared in the core genome, reveals that this diversity did not respect time 
(Fig. 4.1e).  
4.2.2. Genomic diversity of E. faecium within GI tract over time. 
We broadened our analysis by characterizing the pattern of within-patient VREfm 
diversity in four additional patients, identified as pt139, pt1325, pt151 and pt843 (Fig. 
4.2a). References were built for each patient using an isolate cultured at the earliest 
timepoint that we sampled and subjected it to Illumina Miseq and MinION high 
throughput sequencing. All patients other than pt110 were colonized by a single MLST. 
We examined the level of variation for each patient, splitting up our analysis for pt110 by 
the two sublineages. Over the course of VREfm colonization, we found that all patients 
harbor at least 2 unique genotypes based on SNP patterns at any timepoint investigated 
(Fig. 4.2a). The heatmap is scaled from 0 to 15 SNPs per isolate.  
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Figure 4.2 | Unique SNP patterns are detected on each day for 5 VREfm-colonized allo-HSCT 
patients and are acquired at variable rates. a) One isolate per patient was cultured and sequenced by 
both Illumina Miseq and Nanopore MinION platforms. A hybrid assembly was created with Unicyler and 
SNPs were called and corrected with breseq and bcftools. Reads for all patient isolates were aligned to their 
own reference and breseq was used to detect SNPs. A heatmap with a range of 0 to 15 SNPs was plotted, 
with one row per patient. Vertical lines separate each day timepoint. 2 isolates from pt843, #1 and #4 from 
day 12 (indicated by a white circle within the square), had 51 and 49 SNPs respectively that fell in a 757bp 
region in scaffold 5. Therefore, a maximum of 15 SNPs was plotted for these isolates in order to maintain a 
readable scale for the other VREfm strains. b) The proportion of new unique genotypes per day were 
plotted at each day sampled for the 4 out of 5 patients who were sampled on multiple timepoints. Dashed 
lines indicate the last day prior to VREfm expansion in the gut.   
Given our longitudinal sampling of each patient, we next looked at the rate of VRE 
diversification over time. We hereafter use the term genotype to refer to isolates that 
share the same SNPs. Any SNP differences in another isolate would be considered a 
different genotype by this definition (thereby ignoring phylogenetic relationships of how 
one isolate evolves from another). For each patient, we plotted the proportion of unique 
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genotypes seen for the first time at each timepoint, which we refer to as new genotypes 
(Fig. 4.2b). For example, if we consider the isolates from MLST 412 from our first 
patient pt110 (4th row in Fig. 2a, green line in Fig. 2b), we found on day -6 that 3 out of 
the 7 VREfm isolates had acquired SNPs, 2 of which shared the same SNP pattern, while 
4 VREfm strains were identical to the reference. The proportion of unique genotypes on 
day -6 is therefore 42% (3/7). On day 1, 1 isolate was identical to the reference while the 
second VREfm strain had 13 SNPs in a previously unseen pattern, yielding a 50% (1/2) 
ratio. This comparison allows us to track the amount of diversity acquired over time. For 
rapidly evolving VREfm, we would expect to see 100% novel genotypes at each 
timepoint sampled. Instead, we do not detect a consistent trend among the patient 
samples, suggesting that the dynamics of VREfm diversification in the gut are variable. 
The dashed lines indicate the last timepoint at which VREfm occupied less than <10% of 
the microbiota for pt843 (red line) and pt110 (purple line), after which VREfm expanded 
to >99% relative abundance. For pt843 and pt110 sublineage 412, there is an increase in 
proportion of new genotypes detected post-expansion (Fig. 4.2b). 
4.2.3. Putting the heterogeneity of MSKCC patient-derived VRE in a global context  
To compare how related the VREfm isolates are across our MSKCC patients, we 
constructed a maximum-likelihood tree based on the core genome after de novo 
assembling each fecal isolates’ Illumina reads (Fig. 4.3a). For a subset of patients 
analyzed, each patient’s strains cluster together, grouped by their MLST. Additional 
bloodstream Efm isolates cultured at MSKCC are included in the tree. To expand our 
interpretation of VREfm in-host diversity from our patients, we put them in a global 
context by replicating the work recently published on 289 VREfm bloodstream colonies 
isolated across the UK (134). Reads were aligned to Efm reference Aus0004 and a 
consensus sequence was obtained for each isolate. Regions of recombination were 
removed using Gubbins in the original analysis by Raven et al.,; however, at the time of 
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this writing, Gubbins was unable to run for the nearly 400 total isolates. MSKCC isolates 
are distributed within the tree, indicating that our patients are members of the hospital-
associated clade A1 (Fig. 4.3b). We find no geographic signature in our isolate dataset.  
 
Figure 4.3 | VREfm isolates from MSKCC reside within an international collection of hospital-
associated clade A strains and cluster by patient. a) de novo assemblies were constructed from Illumina 
reads using Spades. Core genome alignments were obtained using Roary, and a maximum-likelihood tree 
was created using RAxML’s GTR-GAMMA model. b) Illumina reads were aligned to a published reference 
Aus0004 using SMALT and a consensus sequence was created by replacing SNPs and unmapped regions 
with the called variants and dashes respectively. RAxML was called to construct trees with using the GTR-
CAT -V model. Trees were visualized in iTol. c) Pairwise SNP distances were calculated between BSI and 
fecal isolates (FI) and within FIs. A probability distribution for both sets of distances (BSI-FI; FI-FI) were 
plotted using a kernel density estimate, showing the probability of finding a given number of SNP 
differences between any 2 isolates. d) A similarity matrix shows in each square the percentage of SNPs 
shared by 2 isolates out of the total number of SNPs harbored by both strains.  
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Four patients in this study acquired bloodstream infections (BSI) following VREfm 
domination. The fecal samples chosen for these patients were the closest to the onset of 
bacteremia (Fig. 4.2a). For three out of the four patients, the bloodstream and fecal 
isolates cluster together amongst the UK blood isolate collection (Fig. 4.3b). Pairwise 
SNP distances between blood and fecal isolates (BSI-FI), compared to distances amongst 
fecal isolates alone (FI-FI), were calculated (Fig. 4.3c). Each graph indicates the 
probability of measuring a given number of SNP differences between two isolates. The 
red plot represents the pairwise distances for BSI-FI comparisons, and the blue for FI-FI. 
For three out of the four patients (pt110 MLST736, pt1326 and pt151), the probability 
distributions overlap significantly between the BSI-FI and FI-FI sets with <15 SNP 
differences, indicating that the GI tract seeded the BSI (Fig. 4.3c). For the 4th patient 
pt139, the BSIs and FIs were >1000 SNP differences apart and isolates from the same 
source are highly related to each other (Fig. 4.3d). A similarity matrix for pt139 depicts 
the percentage of SNPs shared by two isolates, and all pairwise comparisons are 
calculated. The dashed square represents the region of the matrix comparing bloodstream 
isolates (y-axis) to fecal (x-axis), showing that no SNPs are harbored in common. The top 
triangle displays the FI-FI comparisons; the binary aspect of this subplot is due to the fact 
that there are 2 genotypes found, one identical to the reference (n=3 isolates) and one 
with a single acquired SNP (n=2 isolates).  
4.2.4. A single nonsynonymous penicillin-binding protein 5 mutation confers a 
fitness advantage in an in vivo model of VRE colonization.  
Given the heterogeneity of VREfm found in colonized patients at any single timepoint, 
we sought to determine when such diversity develops during colonization. Since we lack 
information on how long patients had harbored VREfm in the gut in our time-series data, 
we were limited in our ability to quantify the evolutionary dynamics in patients. 
Therefore, we chose to model the expansion and diversification of VREfm in a mouse 
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model. 8-10 week old naïve C57BL/6J mice were treated with 0.5 g/L ampicillin in their 
drinking water for two days, and colonized with low-dose inoculums of VRE derived 
from our first patient (Fig. 4.4a). We colonized a single mouse with 1-2 CFUs of VREfm. 
During the 133-day course of the experiment, we cultured 4 isolates at 11 different 
timepoints from this single mouse which received continuous ampicillin treatment (Fig. 
4.4b). Whole genome sequencing of the 44 isolates revealed 25 mutations in the 
chromosome. The first SNP mutation appeared at day 15 in a single isolate, and eight 
SNPs were seen only once prior to day 133 (Fig. 4.4c). To estimate the rate of in vivo 
diversity, we plotted the number of SNPs in the four isolates derived from each day and 
found that mutations accumulated at a linear rate (Fig. 4.4d). By day 27, a SNP in the 
penicillin-binding protein 5 (pbp5) appeared and was fixed in the population (Fig. 4.4c). 
A heatmap depicts the number of isolates (0-4) that carry a given SNP at each measured 
day. All isolates cultured post-day 27 harbored the pbp5 mutation, making it the most 
frequent SNP detected (Fig. 4.4e). 22 unique genotypes were found based on the 
chromosomal SNP pattern, and 16 out of the 22 subclones carried the pbp5 mutation, as 
demonstrated in the phylogenic tree, indicating a strong selective advantage (Fig. 4.4f). 
This nonsynomous pbp5 mutation occurred in 434th codon, which changes the 




Figure 4.4 | VREfm rapidly evolves in the GI tract after acquiring a nonsynonymous mutation in the 
gene encoding penicillin binding protein 5 (pbp5). a) Low inocula of VREfm (CFU/ms) are plotted 
relative to the number of mice that were successfully colonized in the inoculated group; n=5 or 10 per 
experimental group. The dose of 0.2 CFUs/ms, which is equivalent to 2 CFUs/ml, infected 1 mouse out of 
10 and b) this individual mouse was followed for a total of 133 days. The density of VREfm was measured 
by plating fecal pellets on selective media. 4 isolates were cultured from fecal content obtained at the 11 
timepoints indicated. c) A heatmap of the 25 SNPs acquired in chromosome across the 44 isolates. The 
pbp5 SNP is indicated. d) The total number of SNPs found among the four isolates at each day are 
indicated over time. e) A table of SNPs mutated in 3 or more isolates. The second column indicates the 
number of isolates that carry that mutation. f) A phylogenetic tree based on the 22 unique genotypes found 
amongst the 44 isolates. The branch of isolates that evolved harboring the pbp5 mutation are indicated by 
the dashed line.  
4.2.5. Metagenomic shotgun data reveals rapid intestinal VRE adaptation that 
occurred weeks post-colonization.  
To track the dynamics of VREfm diversification in the total intestinal population, we 
performed metagenomic sequencing on 6 fecal samples taken from days 1, 27, 49, 77, 
112 and 133. 219 chromosomal SNPs were detected at ≥5% frequency in the VREfm-
dominated intestinal microbiota (Fig. 4.5a). The nonsynomous pbp5 achieved 100% 
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frequency by day 49 and persisted, fitting the pattern of positive selection seen in our 
isolates. During this same timeframe, we observed a rapid evolution of the majority of 
SNPs, only a subset of which were picked up in our isolate screen. While metagenomic 
sequencing provides greater sampling depth, it remains a challenge to determine which 
SNPs co-occur in unique genomes. Therefore, to further characterize the pattern of in 
vivo VREfm evolution over time, we combined our culture-based and deep sequencing 
approaches. We compared the relative abundances of our 22 subclades in the complex 
microbiota by estimating their proportions based on the SNP frequencies from the 
shotgun data (Fig. 4.5b, bottom panel). These refined frequency estimations clarified the 
lineage structure of VREfm over time, demonstrating that four subclades stably coexist 
for months after day 49 (Fig. 4.5c, bottom panel). By day 27, evolved strains 
outcompeted the ancestor, and the four coexisting subclades were derived from the pbp5 
mutant. This phylogenetic pattern was not apparent from the isolate data alone (Fig. 4.5c, 
top panel). Taken together, our data indicates that a strong selective advantage conferred 
by the pbp5 mutation.  
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Figure 4.5 | Sublineages coexist after rapid diversification in which the pbp5 mutation becomes fixed 
in the total intestinal VREfm population. a) Frequency traces are shown for the 219 chromosomal SNP 
picked up by shotgun sequencing of fecal pellets from a single colonized mouse. b) Comparisons of the 
frequency estimates are shown for each SNP found in the isolate collection. The top graph depicts the 
number of isolates that carry a given SNP on each day; the bottom graph shows the percentage of reads that 
had a given SNP as determined from HiSeq metagenomic sequencing data. c) After refining the frequency 
estimates of the 25 isolate-derived chromosomal SNPs by shotgun sequencing, the proportions of related 
strains (as determined in Fig. 4.4f) are plotted over time. Related isolates are grouped into colored bins.  
4.2.6. Parallel evolution and clonal interference characterize the in vivo population 
dynamics of a second VRE isolate.  
To further characterize the dynamic nature of within-host VREfm evolution, we 
reperformed our low-inoculum experiment with a second E. faecium isolate, the ATCC 
700221 strain. We cultured 28 isolates over 7 timepoints during the 62-day course of the 
experiment (Fig. 4.6a). The lab strain acquired 8 chromosomal mutations, 3 of which 
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were nonsynonmous mutations in the pbp5 gene (Fig. 4.6a,b). No isolate harbored more 
than 1 pbp5 SNP (Fig. 4.6a). 8 unique genomes were represented in our isolates (Fig. 
4.6c). Applying the same approach of combining the two sequencing datasets, we tracked 
the dynamics of SNPs identified in the isolates over time based on their shotgun-derived 
frequencies. Interestingly, we see the 2 of the 3 pbp5-mutated subclades change 
frequencies relative to each other (Fig. 4.6d). As strains harboring pbp5-1 drift to lower 
frequencies, those bearing the pbp5-2 mutation rise, which suggests clonal interference 
among the lineages (Fig. 4.6d,e). All three mutations arose in the PBP5 C-terminal 
transpeptidase domain, as was the case in the first VREfm colonizing isolate. Thus, 
experimental evolution highlights the position selection of the pbp5 loci through a 
different pattern of within-host adaptation.  
Figure 4.6 | A second, unrelated VREfm isolate colonizing the GI tract independently evolves 
nonsynonymous mutations in the pbp5 genes. a) 28 isolates from the indicated timepoints (x-axis; from 
day 7 to 62) were cultured over the course of in vivo colonization by ATCC E.fm strain in a single mouse. 8 
SNPs were picked up along the chromosome. b) 7 out of the 8 SNPs were nonsynonymous, 3 of which 
appeared in the pbp5 gene. For the 2 genes that harbored only 1 SNP, a + was indicated if the mutation was 
nonsynonymous. c) A phylogenetic tree inferred from the SNP patterns displayed in a). d) The relative 
frequencies of the 8 unique genotypes fluctuate over time.  
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4.34. DISCUSSION  
There is considerable genomic diversity among enterococcal strains, with genome sizes 
ranging from 2.7 to 3.6 Mb (135-137). Laterally transferred genetic elements make up 
25% of the genome in some isolates (138) and this variation has likely aided hospital 
adaptation of enterococci (139-141). Compared to commensal enterococcal strains, 
multidrug-resistant clinical isolates possess larger genomes through the acquisition of 
foreign genetic material (137). Large-scale phylogenomic studies of Enterococci have 
estimated mutation rates of 7 SNPs per genome per year (134). The rate at which 
enterococci continues to evolve in the hospital environment is of particular clinical 
concern given its morbidity among the critically ill. Recent work has demonstrated that 
individuals can be colonized with multiple enterococcal clones simultaneously, and 
isolates collected at a given day are more similar than those across timepoints within a 
patient (142). How selective forces drive within-host diversification, and what this 
evolutionary pattern looks like, are not well known.   
Herein, we surveyed intra-patient intestinal diversity by culturing isolates at various 
timepoints during VREfm colonization. We assessed the degree of VRE diversification in 
our patients by deeply sampling multiple timepoints, providing cross-sectional and 
longitudinal data. We found at least 2 genotypes amongst the patient isolates at every 
timepoint measured and this diversity did not respect time. Combining single-isolate 
whole-genome comparisons with deep metagenomic sequencing, we characterized the 
rapid adaptive dynamics in an in vivo evolution experiment. Our patient-derived isolate 
acquired a high degree of diversity over 133 days. In both in vivo experiments, evolved 
isolates successfully outcompeted the ancestral strain. Strong selective pressure acting on 
intestinal enterococci was observed by the parallel mutation of the penicillin-binding 
protein 5 (pbp5) gene between the two experiments. The pbp5 mutation shaped the 
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adaptive dynamics of VRE evolving in the GI tract, providing evidence of rapid 
adaptation to antibiotic pressure as a result of positive selection in real-time. 
Enterococci are of particular clinical concern due to their growing resistance to 
antibiotics. Beta-lactams, such as ampicillin, inhibit bacterial growth by modifying and 
thereby inactivating penicillin-binding proteins (PBPs) required for cell wall synthesis. 
Enterococcal strains harbor some intrinsic resistance to beta-lactams by producing PBP5, 
which is chromosomally encoded (143,144). The acquisition of pbp5 gene mutations 
contributed to the high-level ampicillin resistance that healthcare-related E. faecium 
isolates developed in the late 1970s and 1980s (145-147). Increased resistance to 
ampicillin is associated with mutations to the PBP5-encoding gene that further reduce the 
protein’s affinity for beta-lactam antibiotics, such as mutations that result in amino acid 
substitutions near the active site in its transpeptidase domain (148-151). Resistance is 
amplified when multiple mutations are present in the pbp5 gene (151). Here, we 
document the positive fitness advantage conferred in vivo by mutations in the pbp5 gene, 
acquired by intestinal enterococci in as few as two weeks, during continuous ampicillin 
treatment. This data has demonstrates the rapidity in which bacterial pathogens evolve 
under antibiotic pressure.  
4.4. MATERIALS AND METHODS 
4.4.1. VREfm isolate collection and culturing. Stool samples were collected from allo-
HSCT patients in an ongoing IRB-approved study and stored in 2ml freezer vials at 
-80°C. Stored content was thawed and streaked with an inoculating loop onto selective 
Difco Enterococcosel agar supplemented with 10ug/ml vancomycin (EAPv). Fecal pellets 
collected from mice were immediately kept on ice after harvesting and plated the same 
day on EAPv. Plates were incubated aerobically for 48hrs at 37°C and 4-10 colonies were 
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selected and restreaked. Stocks were made by growing a restreaked colony in 5ml Brain 
Heart Infusion liquid media (BHI) overnight and growing in 1:20ml dilution in 20ml BHI 
for 6hrs at 225pm at 37°C. 800ml of the culture was resuspended in 200ml of 75% 
glycerol to obtain 4 15% glycerol stocks per isolate, stored at -80°C. Bloodstream isolates 
were stored by the MSKCC microbiology laboratory and restreaked on EAPv as 
described for fecal isolates.   
4.4.2. Mouse husbandry and in vivo VREfm colonization. in vivo experiments were 
performed in compliance with Memorial Sloan Kettering’s institutional guidelines and 
were approved by its Institutional Animal Care and Use Committee. 8-10 week old wild-
type female C57BL/6 mice were purchased from the Jackson Laboratories. Mice were 
housed in sterile cages with irradiated feed and acidified water. 5ml BHI was inoculated 
with frozen stock overnight and the next day a 1:20ml dilution was incubated for 2.5hrs 
at 225pm at 37°C to obtain a midlog culture of ~6x108 CFU/ml. Serial dilutions were 
performed in PBS. Inocula were plated to determine the CFU input per mouse. Mice were 
pretreated with ampicillin at 0.5g/L for 2 days in the drinking water to abrogate 
colonization resistance, and orally gavaged in 200ul per mouse. Mice were individually 
housed at the time of inoculation. The number of mice per group that were colonized (out 
of 5 or 10 mice total) was assessed on day 1 and day 5 post-challenge by serially diluting 
fecal pellets in PBS and plating on EAPv. Mice in the group that received the lowest 
inocula dose were kept to monitor VREfm and maintained on ampicillin-treated water. 
VREfm density was measured as described every other week henceforth. 
4.4.3. Whole genome sequencing, reference assembly and annotation. Isolates grown 
in BHI until early stationary phase and centrifuged. DNA was extracted using phenol-
chloroform extraction with bead beating and purified with a Qiagen QiaAmp kit. Purified 
DNA was sheared using a Covaris ultrasonicator and prepared for Illumina MiSeq 
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sequencing with a Kapa library preparation kit with Illumina TruSeq adaptors to create 
2x300bp paired-end reads. Fecal pellets sent for shotgun metagenomics were sequenced 
with Illumina HiSeq by 2x100bp paired-end reads. Reads were processed using a custom 
bash shell script. Trimmomatic was used to quality filter raw sequence reads (version 
0.36). Read quality was assessed by FastQC (version 0.11.5).  
For pt110, PacBio reads were assembled with HGAP and iteratively corrected using Pilon 
with Illumina MiSeq reads from the same isolate. A consensus sequence was constructed 
for an isolate from day -6 using breseq SNP and INDEL calls to correct the PacBio 
reference. For all other patients, a hybdrid assembly was constructed with Oxford 
Nanopore MinION and MiSeq reads with Unicycler and iteratively corrected with breseq 
(version 0.31.1). Quality assessment of finished assemblies was performed using QUAST 
(version v4.5). References were annotated using the PATRIC web portal 
4.4.4. Variant detection. Trimmed quality-filtered Illumina reads were aligned to our in-
house references and variants called using breseq. For isolates, the consensus mode was 
used. Shotgun metagenomes were run in the polymorphism mode with default settings, 
which called SNPs at ≥5% frequency. breseq’s annotated output files were parsed and 
analyzed in a custom Python script. A custom bash script was used to determine the 
number of mapped reads for each SNP detected in our isolate dataset within the shotgun 
metagenomic sequencing data. Genotypes were determined based on SNP patterns in a 
custom script written in matlab.  
4.4.5. Construction of phylogenetic trees. Trimmed reads were assembled into contigs 
using the short-read genome assembler SPAdes (version 3.11.1) and annotated with 
PROKKA (version 1.12). Strains were typed by MLST using mlst (version 2.8). Core 
genomes and accessory genes were identified by Roary (version 3.8.2). Maximum-
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likilihood trees were constructed on core genome alignments with RAxML using the 
model GTRCAT if >50 genomes were analyzed or GTRGAMMA if fewer. For large core 
genome alignments, SNPs were called with SNP-sites (version 2.3.2). Maximum-
likelihood trees based on SNPs in the core genomes were created with RAxML using 
ASC-GTRCAT if >50 genomes were analyzed or ASC-GTRGAMMA if fewer.  
For the UK BSI isolates collected by Raven et al., fastq files hosted on the European 
Nucleotide Archive were downloaded by their accession numbers (130). A custom bash 
script was written to replicate this study’s findings. In brief, reads were trimmed and 
aligned to the published genome Aus0004 by SMALT as described (130). For each 
isolate, consensus sequences were obtained by editing the SNPs and unmapped regions 
with the called variants and dashes respectively with vcftools and bcftools. Gubbins was 
used to remove regions of recombination in the original study and failed to run in our 
hands. 
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CHAPTER 5  
CONCLUSIONS AND FUTURE DIRECTIONS 
The intestinal microbiota plays a key role in keeping infection and inflammation at bay. 
Tolerogenic microbes from genera such as Bacteroides and Clostridium are important for 
maintaining homeostasis in the intestinal mucosa, and select bacterial species are 
essential for providing colonization resistance to pathogens. When the intestinal 
microbiota is perturbed by antibiotics, resistant bacteria can colonize the GI tract and 
rapidly reach high densities. Without an intervention to restore the intestinal microbiota, 
pathogens stably persist in the gut for months and the risk of developing bloodstream 
infections increases. In the hospital setting, antibiotic-resistant pathogens can spread 
between patients, acquiring new mutations as bacteria evolve. Using next-generation 
metagenomic sequencing, we characterized the intestinal microbial dynamics that impact 
1) the development of colitis, 2) susceptibility to hospital-associated gram-negative 
pathogens, and 3) intra-species diversity following colonization.  
In Chapter 2, we aimed to determine which specific components of the microbiota 
promote resistance to immunotherapy-associated colitis. We found that members of the 
Bacteroidetes phylum and three of its families are correlated with resistance to the 
development of colitis following CTLA-4 blockade. We also found that a lack of genetic 
pathways involved in polyamine transport and B vitamin biosynthesis is associated with 
an increased risk of colitis. Whether or not B vitamins play a direct role in the modulating 
colitis risk or are a signature of a healthy microbiota remains to be determined.  
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In Chapter 3, we asked which intestinal bacteria provide resistance to the antibiotic-
resistant gram-negative Klebsiella pneumonia (Kp). We used an in vivo mouse model to 
differentially alter intestinal microbial communities using antibiotic treatment and 
bacterial adoptive transfers. Colonization resistance was restored when reconstituting 
mice with bacteria cultured anaerobically. We found that higher abundances of Clostridia 
class members is correlated with lower Kp density. Using statistical models on our time-
series sequencing data, we also found that the certain clostridial OTUs can help predict 
whether Kp colonization resolves over time. A major challenge in constructing bacterial 
consortium to resolve infection is identifying the right combination of isolates, as the 
microbes must both engraft in the host and eliminate the colonizing pathogen. The 
modeling analyses presented here have identified a select number of isolates that should 
tested further in in vivo adoptive transfer experiments. Ideally, future studies would test 
these candidates from a bank of human-derived bacterial isolates. Additionally, further 
studies are required to understand how such a consortium resolves K. pneumonia 
colonization. The work presented in this thesis suggests that short-chain fatty acids might 
play a role, as clostridial species are known producers in the colon, through a direct 
mechanism of inhibition.  
In Chapter 4, we sought to characterize the temporal dynamics of how E. faecium, which 
exists as a commensal and a pathogen in patients, evolves within the host as it colonizes 
the gut. Using a culture-based approach, we found multiple genotypes per timepoint in 
VRE-colonized allo-HSCT patients. To understand the rate that VRE acquires this 
diversity, we followed the expansion and colonization of a single CFU of E. faecium 
inoculated into an antibiotic-treated mouse. We found many mutations that evolve rapidly 
at roughly three weeks post-colonization, and estimated that four subclades remain in 
stable proportions following this rapid evolution. In two independent mouse experiments, 
we detected nonsynomous SNPs in the transpeptidase-encoding region of the penicillin-
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binding protein 5 (pbp5) gene, which is known to accumulate mutations in clinical 
isolates and confers ampicillin resistance. Our results indicate that VRE can rapidly adapt 
within the GI tract in response to selective antibiotic pressure. Whether or not the 
evolutionary pattern of VRE in our mouse experiment is stochastic can be answered by 
inoculating additional mice with the same VRE isolate. Work has currently been 
undertaken to formally describe the mutation rate and fitness costs observed in our in vivo 
experiments. The mathematical modeling used here to analyze the population dynamics 
of VRE can also be applied to high-throughput shotgun data of patient samples. The 
Pamer lab has deeply sequenced fecal content taken serially from a number of allo-HSCT 
patients who have been colonized by VRE. With this dataset, we can identify all 
mutations acquired in VRE in the gut to further understand how rapidly VRE diversifies 
in patients and if multiple lineages coexist and compete.  
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